Mirion Technologies, Inc 10-Q for FY2026 Q3
Mirion Technologies, Inc. (MIR)
10-Q
2026-10-28
For: 2026-09-30
View Original
Added on
October 28, 2026
About this 10-Q
Mirion Technologies, Inc filed this 10-Q on October 28, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Mirion Technologies reported third-quarter revenues of $277.8 million, up from $223.1 million, net income of $7.8 million versus $3.1 million, and backlog of $1,248.2 million at September 30, 2026. Nuclear & Safety generated 69.8% of quarterly revenue. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $277.8M
- up 24.5% from $223.1M a year earlier
- Net income
- $7.4M
- up 155.2% from net income of $2.9M a year earlier
- Diluted EPS
- $0.03
- up 200.0% from $0.01 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
For the quarterly period ended September 30, 2026
OR
For the transition period from __________ to __________
Commission File Number: 001-39352
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) | |||||||
(Address of Principal Executive Office)
(770 ) 432-2744
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☒ | Accelerated Filer | ☐ | |||||||||
| Non-accelerated Filer | ☐ | Smaller Reporting Company | |||||||||
| Emerging Growth Company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒
As of October 22, 2026, there were 239,732,572 shares of Class A common stock, $0.0001 par value per share, and 5,759,555 shares of Class B common stock, $0.0001 par value per share, issued and outstanding.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995 that reflect future plans, estimates, beliefs, and expected performance. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future operating results and financial position, our business strategy and plans, our objectives for future operations, macroeconomic trends, including the impact of tariffs and global trade relations, macro trends in cancer care, nuclear power and small modular reactor industries and our competitive positioning are forward-looking statements. This includes, without limitation, statements under Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial position, capitalization and capital structure, indebtedness, business strategy, and the plans and objectives of management for future operations, market share and products sales, future market opportunities, future manufacturing capabilities and facilities, future sales channels and strategies, goodwill impairment, backlog, our supply chain challenges, matters affecting Russia, relations between the United States and China, conflict in the Middle East (including the U.S.-Israel-Iran conflict), foreign exchange, tariffs or other trade disruptions, interest rate and inflation trends, any merger, acquisition, divestiture or investment activity, including integration of previously completed mergers and acquisitions, or other strategic transactions and investments, legal claims, litigation, arbitration or similar proceedings, including with respect to customer disputes, and the future or expected impact on us of any epidemic, pandemic or other crises. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. When used in this Quarterly Report on Form 10-Q, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “scheduled,” “should,” “strive,” “seeks,” “plans,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When we discuss our strategies or plans we are making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, our management.
The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following risks, uncertainties and other factors:
•geopolitical and trade conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict in the Middle East, risks related to tariffs and global trade relations, export controls, foreign localization requirements and other trade barriers, and risks of slowing economic growth or economic recession in the United States and globally;
•the effect of the U.S.-Israel-Iran conflict, which has had immediate and substantial effects on global trade, energy markets and financial markets;
•developments in government spending budgets in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgeting priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government's failure to raise the debt ceiling;
•our ability to manage our supply chain or difficulties with third-party manufacturers;
•risks related to government contracts including our ability to mitigate risks associated with long-term fixed price contracts;
•our ability to predict our future operational results;
•risks related to the public's perception of nuclear radiation and nuclear technologies;
•risks related to information technology disruptions or security issues, including cyberattacks and data or systems breaches;
•risks related to the use of artificial intelligence and machine learning technologies in our operations;
•our ability to manage our independent sales representatives, distributors, and original equipment manufacturers;
•our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures and investments, including any synergies or internal restructuring and improvement efforts;
•our ability to issue debt, equity or equity-linked securities in the future;
•risks related to changes in tax law and ongoing tax audits;
•our ability to attract, train, and retain key members of our leadership team and other qualified personnel;
•risks related to the costs or liabilities associated with product liability claims;
•risks related to the adequacy of our insurance coverage;
•risks related to the global scope of our operations, including operations in international and emerging markets;
2
•risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates, tariffs, reciprocal and retaliatory tariffs and other tariff-related measures, and inflation, including the impact on our debt service cost;
•our ability to comply with various laws and regulations and the costs associated with legal compliance;
•risks related to the uncertainty and outcome of any legal claims, litigation, arbitration, government and regulatory proceedings, investigations and inquiries;
•risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims;
•liabilities associated with environmental, health, and safety matters; and
•other risks and uncertainties indicated in our Annual Report on Form 10-K for the year ended December 31, 2025 and this Quarterly Report on Form 10-Q, including those under the heading “Risk Factors,” and other documents filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”) by us.
There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.
Forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this Quarterly Report on Form 10-Q or any earlier date specified for such statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
We intend to announce material information to the public through the Mirion Investor Relations website, available at ir.mirion.com, SEC filings, press releases, public conference calls, and public webcasts. We use these channels, as well as social media, to communicate with our investors, customers and the public about our company, our offerings and other issues. It is possible that the information we post on our website or social media could be deemed to be material information. As such, we encourage investors, the media, and others to follow the channels listed above, including the social media channels listed on our investor relations website, and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which we will announce information will be posted on the investor relations website.
3
TABLE OF CONTENTS
4
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
as of September 30, 2026 and December 31, 2025 | |||||
for the three and nine months ended September 30, 2026 and September 30, 2025 | |||||
for the three and nine months ended September 30, 2026 and September 30, 2025 | |||||
for the three and nine months ended September 30, 2026 and September 30, 2025 | |||||
for the nine months ended September 30, 2026 and September 30, 2025 | |||||
5
Mirion Technologies, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In millions, except share data)
| September 30, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Accounts receivable, net of allowance for doubtful accounts | |||||||||||
| Costs in excess of billings on uncompleted contracts | |||||||||||
| Inventories | |||||||||||
| Prepaid expenses and other current assets | |||||||||||
| Total current assets | |||||||||||
| Property, plant, and equipment, net | |||||||||||
| Operating lease right-of-use assets | |||||||||||
| Goodwill | |||||||||||
| Intangible assets, net | |||||||||||
| Other assets | |||||||||||
| Total assets | $ | $ | |||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | $ | |||||||||
| Deferred contract revenue | |||||||||||
| Debt, current | |||||||||||
| Operating lease liabilities, current | |||||||||||
| Derivative liabilities, current | |||||||||||
| Accrued expenses and other current liabilities | |||||||||||
| Total current liabilities | |||||||||||
| Debt, non-current | |||||||||||
| Convertible debt | |||||||||||
| Operating lease liabilities, non-current | |||||||||||
| Deferred income taxes, non-current | |||||||||||
| Other liabilities | |||||||||||
| Total liabilities | |||||||||||
| Commitments and contingencies (Note 11) | |||||||||||
| Stockholders’ equity (deficit): | |||||||||||
Class A common stock; $ | |||||||||||
Class B common stock; $ | |||||||||||
Treasury stock, at cost; | ( | ( | |||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | ( | ( | |||||||||
| Accumulated other comprehensive loss | ( | ( | |||||||||
| Mirion Technologies, Inc. stockholders’ equity | |||||||||||
| Noncontrolling interests | |||||||||||
| Total stockholders’ equity | |||||||||||
| Total liabilities and stockholders’ equity | $ | $ | |||||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
6
Mirion Technologies, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In millions, except per share data)
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Product | $ | $ | $ | $ | |||||||||||||||||||
| Service | |||||||||||||||||||||||
| Total revenues | |||||||||||||||||||||||
| Cost of revenues: | |||||||||||||||||||||||
| Product | |||||||||||||||||||||||
| Service | |||||||||||||||||||||||
| Total cost of revenues | |||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Selling, general and administrative | |||||||||||||||||||||||
| Research and development | |||||||||||||||||||||||
| Total operating expenses | |||||||||||||||||||||||
| Income from operations | |||||||||||||||||||||||
| Other expense (income): | |||||||||||||||||||||||
| Interest expense | |||||||||||||||||||||||
| Interest income | ( | ( | ( | ( | |||||||||||||||||||
| Loss on debt extinguishment | |||||||||||||||||||||||
| Foreign currency loss (gain), net | ( | ( | |||||||||||||||||||||
| Other expense, net | |||||||||||||||||||||||
| Income before income taxes | |||||||||||||||||||||||
| Income tax expense (benefit) | ( | ( | |||||||||||||||||||||
| Net income | |||||||||||||||||||||||
| Income attributable to noncontrolling interests | |||||||||||||||||||||||
| Net income attributable to Mirion Technologies, Inc. | $ | $ | $ | $ | |||||||||||||||||||
| Earnings per common share attributable to Mirion Technologies, Inc.: | |||||||||||||||||||||||
| Basic | $ | $ | $ | $ | |||||||||||||||||||
| Diluted | $ | $ | $ | $ | |||||||||||||||||||
| Weighted average common shares outstanding: | |||||||||||||||||||||||
| Basic | |||||||||||||||||||||||
| Diluted | |||||||||||||||||||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
7
Mirion Technologies, Inc.
Condensed Consolidated Statements of Comprehensive Income (Loss)
(Unaudited)
(In millions)
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Net income | $ | $ | $ | $ | |||||||||||||||||||
| Other comprehensive (loss) income, net of tax: | |||||||||||||||||||||||
| Foreign currency translation (loss) gain, net of tax | ( | ( | ( | ||||||||||||||||||||
| Unrealized gain (loss) on net investment hedges, net of tax | ( | ||||||||||||||||||||||
| Unrealized (loss) gain on cash flow hedges, net of tax | ( | ( | |||||||||||||||||||||
| Other comprehensive income (loss), net of tax | ( | ( | |||||||||||||||||||||
| Comprehensive income | |||||||||||||||||||||||
| Less: Comprehensive income (loss) attributable to noncontrolling interest | ( | ||||||||||||||||||||||
| Comprehensive income attributable to Mirion Technologies, Inc. stockholders | $ | $ | $ | $ | |||||||||||||||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
8
Mirion Technologies, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)
(In millions, except share amounts)
| Class A Common Stock | Class B Common Stock | Treasury Stock | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive (Loss) Income | Noncontrolling Interests | Total Stockholders’ Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance December 31, 2024 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued for vested restricted stock units | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued from treasury stock for vested restricted stock units | — | — | — | ( | ( | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares repurchased to satisfy tax withholdings for vesting restricted stock units | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock compensation to directors in lieu of cash compensation | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of shares of class B common stock to class A common stock | — | ( | — | — | — | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock | ( | — | — | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance March 31, 2025 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued for vested restricted stock units | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued from treasury stock for vested restricted stock units | — | — | — | ( | ( | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares repurchased to satisfy tax withholdings for vesting restricted stock units | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock compensation to directors in lieu of cash compensation | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of shares of class B common stock to class A common stock | — | ( | — | — | — | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of capped calls related to convertible debt, net of tax | — | — | — | — | — | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance June 30, 2025 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
9
| Stock issued for vested restricted stock units | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued from treasury stock for vested restricted stock units | — | — | — | ( | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock compensation to directors in lieu of cash compensation | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of shares of class B common stock to class A common stock | — | ( | — | — | — | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of class A common stock under a direct registered offering, net of offering costs | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of capped calls related to convertible debt | — | — | — | — | — | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax impact of capped calls related to convertible debt | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | — | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance September 30, 2025 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Class A Common Stock | Class B Common Stock | Treasury Stock | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive (Loss) Income | Noncontrolling Interests | Total Stockholders’ Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance December 31, 2025 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued for vested restricted stock units | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued from treasury stock for vested restricted stock units | — | — | — | ( | ( | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares repurchased to satisfy tax withholdings for vesting restricted stock units | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock compensation to directors in lieu of cash compensation | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of shares of class B common stock to class A common stock | — | ( | — | — | — | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax impact of capped calls related to convertible debt | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | — | — | — | — | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance March 31, 2026 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
10
| Stock issued for vested restricted stock units | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued from treasury stock for vested restricted stock units | — | — | — | ( | ( | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares repurchased to satisfy tax withholdings for vesting restricted stock units | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock compensation to directors in lieu of cash compensation | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of shares of class B common stock to class A common stock | — | ( | — | — | — | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax impact of capped calls related to convertible debt | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | — | — | — | — | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance June 30, 2026 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued for vested restricted stock units | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock issued from treasury stock for vested restricted stock units | — | — | — | ( | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares repurchased to satisfy tax withholdings for vesting restricted stock units | ( | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock compensation to directors in lieu of cash compensation | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock | ( | — | — | — | ( | — | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise tax on purchases of treasury stock | — | — | — | — | — | ( | — | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax impact of capped calls related to convertible debt | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance September 30, 2026 | $ | $ | $ | ( | $ | $ | ( | $ | ( | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
11
Mirion Technologies, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In millions)
| Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||
| OPERATING ACTIVITIES: | |||||||||||
| Net income | $ | $ | |||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization expense | |||||||||||
| Stock-based compensation expense | |||||||||||
| Loss on debt extinguishment | |||||||||||
| Amortization of debt issuance costs | |||||||||||
| Provision for doubtful accounts | |||||||||||
| Inventory obsolescence write down | |||||||||||
| Change in deferred income taxes | ( | ( | |||||||||
| Loss on disposal of property, plant, and equipment | |||||||||||
| Loss (gain) on foreign currency transactions | ( | ||||||||||
| Amortization of inventory step-up from purchase accounting | |||||||||||
| Other | |||||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | ( | ||||||||||
| Costs in excess of billings on uncompleted contracts | ( | ( | |||||||||
| Inventories | ( | ( | |||||||||
| Prepaid expenses and other current assets | ( | ( | |||||||||
| Accounts payable | ( | ||||||||||
| Accrued expenses and other current liabilities | ( | ( | |||||||||
| Deferred contract revenue and liabilities | ( | ||||||||||
| Other assets | ( | ||||||||||
| Other liabilities | ( | ( | |||||||||
| Net cash provided by operating activities | |||||||||||
| INVESTING ACTIVITIES: | |||||||||||
| Purchases of property, plant, and equipment and badges | ( | ( | |||||||||
| Proceeds from net investment hedge derivative contracts | |||||||||||
| Proceeds from disposal of property, plant, and equipment and badges | |||||||||||
| Acquisitions of businesses, net of cash and cash equivalents acquired | ( | ( | |||||||||
| Net cash used in investing activities | ( | ( | |||||||||
| FINANCING ACTIVITIES: | |||||||||||
| Stock repurchased to satisfy tax withholding for vesting restricted stock units | ( | ( | |||||||||
| Purchases of stock for treasury | ( | ( | |||||||||
| Proceeds from issuance of convertible senior notes, net of bank costs | |||||||||||
| Third-party issuance costs | ( | ||||||||||
| Purchases of capped calls related to convertible senior notes | ( | ||||||||||
| Issuances of common stock | |||||||||||
| Common stock issuance costs | ( | ||||||||||
| Term loan principal repayments | ( | ||||||||||
| Financing costs | ( | ||||||||||
| Proceeds from cash flow hedge derivative contracts | |||||||||||
| Other financing | ( | ( | |||||||||
| Net cash (used in) provided by financing activities | ( | ||||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | ( | ||||||||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | ( | ||||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | $ | |||||||||
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
12
Mirion Technologies, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Nature of Business and Summary of Significant Accounting Policies
Nature of Business
Mirion Technologies, Inc. (“Mirion,” the “Company,” “we,” “our,” or “us” and formerly GS Acquisition Holdings Corp II (“GSAH”)) is a global provider of radiation detection, measurement, analysis, and monitoring products and services to the medical, nuclear, and defense end markets. On October 20, 2021, Mirion Technologies, Inc. was formed when it consummated its business combination with GSAH.
We provide products and services through our two
Basis of Presentation and Principles of Consolidation
The accompanying unaudited Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for financial statements and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial information. The interim unaudited Condensed Consolidated Financial Statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation of the results for the periods presented and should be read in conjunction with the audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2025, which include a complete set of footnote disclosures, including our significant accounting policies included in our Annual Report on Form 10-K. The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned and majority-owned or controlled subsidiaries. For consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocated to noncontrolling interests is reported as “Income attributable to noncontrolling interests” in the unaudited Condensed Consolidated Statements of Operations. All intercompany accounts and transactions have been eliminated in consolidation.
Segments
13
Use of Estimates
Significant Accounting Policies
There have been no material changes in our significant accounting policies during the nine months ended September 30, 2026, as compared to the significant accounting policies described in Note 1 to the audited consolidated financial statements on Form 10-K for the period ended December 31, 2025.
Accounts Receivable and Allowance for Doubtful Accounts
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets are primarily comprised of various prepaid assets including prepaid insurance, short-term marketable securities, and income tax receivables.
The components of prepaid expenses and other current assets consist of the following (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| Prepaid insurance | $ | $ | |||||||||
| Prepaid vendor deposits | |||||||||||
| Prepaid software expenses | |||||||||||
| Restricted cash | |||||||||||
| Short-term marketable securities | |||||||||||
| Income tax receivable and prepaid income taxes | |||||||||||
| Other tax receivables | |||||||||||
| Other current assets | |||||||||||
| $ | $ | ||||||||||
Facility and Equipment Decommissioning Liabilities
14
Convertible Senior Notes
In May 2025, the Company issued in a private offering $400.0 million aggregate principal amount of 0.25 % Convertible Senior Notes due 2030 (the “2030 Notes”), including the initial purchasers' exercise in full of their option to purchase additional Notes. In September 2025, the Company issued in a private offering $375.0 million aggregate principal amount of 0.00 % Convertible Senior Notes due 2031 (the “2031 Notes”), including the initial purchasers' exercise in full of their option to purchase additional Notes. The 2030 Notes and 2031 Notes are accounted for in accordance with ASC 470-20, “Debt with Conversion and Other Options”. See Note 9, Convertible Debt, for additional details.
Revenue Recognition
The Company recognizes revenue from arrangements that include performance obligations to design, engineer, manufacture, deliver, and install products. If a performance obligation does not qualify for over-time revenue recognition, revenue is then recognized at the point-in-time in which control of the distinct good or service is transferred to the customer, typically based upon the terms of delivery.
Revenue derived from passive dosimetry and analytical services is of a subscription nature and is provided to customers on an agreed-upon recurring monthly, quarterly or annual basis. Revenue is recognized ratably over the service period as the service is continuous, and no other discernible pattern of recognition is evident.
Contract Balances
Revenue earned in excess of billings on contracts in progress (contract assets) are classified in the unaudited Condensed Consolidated Balance Sheets in costs in excess of billings on uncompleted contracts. Amounts billed in excess of revenue earned (contract liabilities) are included in deferred contract revenue. Our billing terms for these over-time contracts are generally based on achieving specified milestones. The differences between the timing of our revenue recognized (based on costs incurred) and customer billings (based on contractual terms) results in changes to our contract asset or contract liability positions.
Milestone billing is aligned to the timing of the associated performance of the Company at the contract onset and generally occurs multiple times in a given twelve-month period. Unexpected project delays could impact the contract asset or liability position during the course of a contract. Contract asset balances are reviewed by management for future credit losses by considering factors such as historical experience, the customers' financial condition and current economic conditions. In circumstances where the Company is aware of a specific customer's inability to meet its financial and contractual obligations, a specific reserve is recorded against the contract asset. As of September 30, 2026, one project accounts for more than 10% of the contract asset balance (10.2 %). For more information, see Note 3, Contracts in Progress.
Remaining Performance Obligations
Disaggregation of Revenues
A disaggregation of the Company’s revenues by segment, geographic region, timing of revenue recognition and product category is provided in Note 15, Segment Information.
Treasury Stock
We account for treasury stock under the cost method pursuant to the provisions of ASC 505-30, “Treasury Stock”. Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account, treasury stock. The equity accounts that were originally credited for the original share issuance, common stock and additional paid-in capital, remain intact.
15
When treasury shares are reissued at a price higher than cost, the difference is recorded as a component of additional paid-in capital in the unaudited Condensed Consolidated Balance Sheets. When treasury stock is re-issued at a price lower than its cost, the difference is recorded as a component of additional paid-in capital to the extent that previously recorded gains exist to offset the losses. If there are no treasury stock gains in additional paid-in-capital, the losses upon re-issuance of treasury stock are recorded as a reduction of retained earnings in the unaudited Condensed Consolidated Balance Sheets. Treasury stock is reissued on a FIFO cost flow basis to compute excesses and deficiencies upon subsequent share reissuance.
Concentrations of Risk
Financial instruments that are potentially subject to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company maintains cash in bank deposit accounts that, at times, may exceed the insured limits of the local country. The Company has not experienced any losses in such accounts.
Recent Accounting Pronouncements
Accounting Guidance Issued but not yet Adopted
In October 2023, the FASB issued ASU 2023-06, “Disclosure Improvements.” ASU 2023-06 clarifies or improves disclosure and presentation requirements of a variety of topics. For entities subject to the SEC’s existing disclosure requirements, the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the codification and will not become effective for any entity. The Company is currently evaluating the impact of this ASU.
In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive
Income—Expense Disaggregation Disclosures.” The ASU will improve the decision usefulness for investors by requiring public business entities to disclose more detailed information about their expenses such as (a) inventory and manufacturing expense, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, etc. The amendments will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments will be applied prospectively with an option for a retrospective application. The Company is evaluating the impact of this new standard and believes that the adoption will result in additional disclosures, but does not expect it to have any other impact on its consolidated financial statements.
In September 2025, the FASB issued ASU 2025-06, “Intangibles—Goodwill and Other—Internal-Use Software.” ASU 2025-06 amends certain aspects of the accounting for and disclosure of software costs under ASC 350-40. The ASU makes targeted improvements to capitalization of costs for software developed or obtained for internal use. The amendment is expected to simplify the analysis for internal-use software cost capitalization, as entities no longer will be required to align capitalization to project stages that are not applicable to an agile development environment. The amendments will be effective for fiscal years beginning after December 15, 2027, in addition to the interim periods within those annual reporting periods, with early adoption permitted at the beginning of a reporting period. The Company is currently evaluating the impact of this ASU and plans to early adopt with prospective application beginning in fiscal year 2027.
In December 2025, the FASB issued ASU 2025-10, "Accounting for Government Grants Received by Business Entities." ASU 2025-10 establishes authoritative guidance on the recognition, measurement, and presentation of government grants received by business entities, reducing diversity in current practice. The amendments require that a grant be recognized when it is probable that the entity will comply with the attached conditions and the grant will be received. Entities may elect to recognize grants related to assets as deferred income or as an adjustment to the cost basis of the asset. The amendments will be effective for fiscal years beginning after December 15, 2028, in addition to the interim periods within those annual reporting periods, with early adoption permitted at the beginning of a reporting period. The Company is currently evaluating the impact of ASU 2025-10 and plans to early adopt beginning in fiscal year 2027.
16
2. Business Combinations, Acquisitions, and Business Disposals
All acquisitions are accounted for under the acquisition method of accounting, and the related assets acquired and liabilities assumed are recorded at fair value. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains the information used for the purchase price allocation during due diligence and through other sources. In the months after closing, as the Company obtains additional information about the acquired assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. The fair values of acquired intangibles are determined based on estimates and assumptions that are deemed reasonable by the Company. Significant assumptions include the discount rates and certain assumptions that form the basis of the forecasted results of the acquired business including revenue, earnings before interest, taxes, depreciation and amortization (“EBITDA”), and growth rates. These assumptions are forward looking and could be affected by future economic and market conditions. Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required.
Purchases of acquired businesses resulted in the recognition of goodwill in the Company’s Consolidated Financial Statements, which is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. The goodwill is not amortized but some portion may be deductible for income tax purposes. This goodwill recorded includes the following:
•The expected synergies and other benefits that we believe will result from combining the operations of the acquired business with the operations of Mirion;
•Any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products;
•The value of the existing business as an assembled collection of net assets versus if the Company had acquired all of the net assets separately.
Purchase of Certrec
On July 31, 2025, Mirion acquired 100 % of the equity interest of Certrec for approximately $82.9 million of gross purchase consideration ($80.6 million, net of cash). Certrec is a leading supplier of regulatory compliance and digital integration solutions for the energy industry. Mirion management believes the Certrec business will be pivotal in expanding our offerings in the nuclear power market and further strengthen the development of Mirion's digital ecosystem.
Transaction costs related to Certrec were not material for the three and nine months ended September 30, 2026.
Purchase of Paragon Energy Solutions
On December 1, 2025, Mirion acquired 100 % of the outstanding membership interest of WCI-Gigawatt Intermediate Holdco, LLC, the indirect parent of Paragon Energy Solutions, LLC (“Paragon”) for $588.6 million of gross purchase consideration ($581.5 million, net of cash and net working capital adjustment). As part of the Nuclear & Safety segment, Paragon is a leading provider of highly engineered solutions for large-scale nuclear power plants and small modular reactors (“SMRs”) in the United States. Mirion management believes that Paragon will provide Mirion's nuclear power customers with a more comprehensive suite of product offerings and services to meet their growing needs. Additionally, the addition of Paragon significantly enhances Mirion's presence in the U.S. nuclear power market and the developing SMR commercial entrants.
Transaction costs related to Paragon were not material for the three and nine months ended September 30, 2026.
17
Fair value of Assets Acquired in 2025
The following table summarizes the total business enterprise value, comprised of the fair value of net assets acquired for the prior year acquisitions (in millions):
| Certrec | Paragon | ||||||||||||||||||||||
| Date of acquisition | July 31, 2025 | December 1, 2025 | |||||||||||||||||||||
| Segment | Nuclear & Safety | Nuclear & Safety | |||||||||||||||||||||
| Final Amounts at June 30, 2026 | Provisional Amounts at December 31, 2025 | Measurement-period Adjustments | Provisional Amounts at September 30, 2026 | ||||||||||||||||||||
Goodwill (1) | $ | $ | $ | ( | $ | ||||||||||||||||||
| Amortizable intangible assets: | |||||||||||||||||||||||
Developed technology (2) | |||||||||||||||||||||||
Customer relationships (3) | |||||||||||||||||||||||
Trade names (4) | |||||||||||||||||||||||
Leasehold improvements (5) | |||||||||||||||||||||||
Backlog (6) | |||||||||||||||||||||||
| Total amortizable intangible assets | $ | $ | $ | $ | |||||||||||||||||||
| Tangible assets and liabilities: | |||||||||||||||||||||||
| Cash | $ | $ | $ | $ | |||||||||||||||||||
| Restricted cash—current | |||||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||||
| Costs in excess of billings | ( | ||||||||||||||||||||||
| Inventories | ( | ||||||||||||||||||||||
| Prepaid expenses and other currents assets | |||||||||||||||||||||||
| Property, plant, and equipment, net | |||||||||||||||||||||||
| Other assets | ( | ||||||||||||||||||||||
| Accounts payable | ( | ( | ( | ||||||||||||||||||||
| Deferred contract revenue | ( | ( | ( | ( | |||||||||||||||||||
| Accrued expenses and other current liabilities | ( | ( | ( | ( | |||||||||||||||||||
| Deferred income taxes, non-current | ( | ( | |||||||||||||||||||||
| Other liabilities, non-current | ( | ( | ( | ||||||||||||||||||||
| Net tangible assets acquired | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
| Purchase consideration | $ | $ | $ | $ | |||||||||||||||||||
| Less: cash and restricted cash acquired | |||||||||||||||||||||||
| GAAP purchase consideration, net of cash acquired | $ | $ | $ | $ | |||||||||||||||||||
(1)The goodwill of $55.7 million and $343.6 million, respectively, represents the excess of the gross consideration transferred over the fair value of the underlying net tangible and identifiable intangible assets acquired and liabilities assumed and is attributable to the acquired assembled workforce and expected revenue and cost synergies. A portion of the goodwill recognized is expected to be deductible for income tax purposes. The purchase price allocation for Paragon has not been finalized, and we expect to finalize the valuation report and complete the purchase price allocation no later than one-year from the acquisition date.
(2)The useful life for developed technology ranges from 5 15
(3)The useful life for customer relationships is 10
(4)The useful life for trade names is 10
(5)The useful life for leasehold improvements is 3.6
(6)The useful life for backlog is 3
18
The estimated fair values of all assets acquired and liabilities assumed in the Paragon acquisition are provisional and may be revised as a result of additional information obtained during the measurement period of up to one year from the acquisition date, including but not limited to costs in excess of billings, intangible assets, deferred revenue balances and the valuation of tax accounts.
Unaudited Pro Forma Financial Information
The following unaudited pro forma financial information presents the Company's results of operations for the three and nine months ended September 30, 2025, to illustrate the estimated effects of the acquisitions of Certrec and Paragon as if they had occurred on January 1, 2024. The pro forma financial information is presented for comparative purposes only and is not necessarily indicative of the Company's operating results that may have actually occurred had the acquisitions been completed on January 1, 2024. The unaudited pro forma financial information does not reflect the expected realization of any anticipated cost savings, operating efficiencies, or other synergies that may have been associated with the acquisitions.
| (amounts in millions) | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2025 | |||||||||
| Total revenues | $ | $ | |||||||||
| Net loss | ( | ( | |||||||||
| Net loss attributable to Mirion Technologies, Inc. stockholders | ( | ( | |||||||||
The unaudited pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the acquisitions had occurred on January 1, 2024, to give effect to certain events the Company believes to be directly attributable to the acquisitions. These pro forma adjustments primarily include:
•A net increase in cost of revenues, depreciation, and amortization expense that would have been recognized due to acquired inventory, property, plant and equipment, operating leases and intangible assets;
•An increase in amortization of deferred financing costs that would have been recognized due to the convertible senior notes obtained to finance the transaction; and
•A change in income tax expense to reflect the income tax effect of the pro forma adjustments based upon an estimated blended statutory rate of 23%.
3. Contracts in Progress
Costs and billings on uncompleted construction-type contracts consist of the following (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| Costs incurred on contracts (from inception to completion) | $ | $ | |||||||||
| Estimated earnings | |||||||||||
| Contracts in progress | |||||||||||
| Less: billings to date | ( | ( | |||||||||
| $ | $ | ||||||||||
The balances reflected in the table above include the open projects acquired in the Paragon purchase; refer to Note 2, Business Combinations, Acquisitions, and Business Disposals, for additional information regarding the Paragon purchase.
19
The carrying amounts related to uncompleted construction-type contracts are included in the accompanying unaudited Condensed Consolidated Balance Sheets under the following captions (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| Costs and estimated earnings in excess of billings on uncompleted contracts – current | $ | $ | |||||||||
Costs and estimated earnings in excess of billings on uncompleted contracts – non-current (1) | |||||||||||
Billings in excess of costs and estimated earnings on uncompleted contracts – current (2) | ( | ( | |||||||||
Billings in excess of costs and estimated earnings on uncompleted contracts – non-current (3) | ( | ( | |||||||||
| $ | $ | ||||||||||
(1) Included in other assets within the unaudited Condensed Consolidated Balance Sheets.
(2) Included in deferred contract revenue – current within the unaudited Condensed Consolidated Balance Sheets.
For the three and nine months ended September 30, 2026, the Company has recognized revenue of $7.4 million and $34.4 million related to the contract liabilities balance as of December 31, 2025, respectively.
4. Inventories
The components of inventories consist of the following, net of reserves (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| Raw materials | $ | $ | |||||||||
| Work in progress | |||||||||||
| Finished goods | |||||||||||
| $ | $ | ||||||||||
5. Property, Plant and Equipment, Net
Property, plant and equipment, net consist of the following (in millions):
| Depreciable Lives | September 30, 2026 | December 31, 2025 | |||||||||||||||
| Land, buildings, and leasehold improvements | $ | $ | |||||||||||||||
| Machinery and equipment | |||||||||||||||||
| Badges | |||||||||||||||||
| Furniture, fixtures, computer equipment and other | |||||||||||||||||
| Software development costs | |||||||||||||||||
Construction in progress (1) | — | ||||||||||||||||
| Less: accumulated depreciation | ( | ( | |||||||||||||||
| $ | $ | ||||||||||||||||
(1) Includes $14.5 million and $3.9 million of Construction in progress for internally developed software as of September 30, 2026, and December 31, 2025, respectively.
20
Total depreciation expense included in costs of revenues and operating expenses was as follows (in millions):
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Depreciation expense in: | |||||||||||||||||||||||
| Cost of revenues | $ | $ | $ | $ | |||||||||||||||||||
| Operating expenses | $ | $ | $ | $ | |||||||||||||||||||
6. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| Compensation and related benefit costs | $ | $ | |||||||||
| Customer deposits | |||||||||||
| Accrued commissions | |||||||||||
| Accrued warranty costs | |||||||||||
| Non-income taxes payable | |||||||||||
| Pension and other post-retirement obligations | |||||||||||
| Income taxes payable | |||||||||||
| Restructuring | |||||||||||
| Deferred and contingent consideration | |||||||||||
| Other accrued expenses | |||||||||||
| Total | $ | $ | |||||||||
7. Goodwill and Intangible Assets
Goodwill
Goodwill is calculated as the excess of consideration transferred over the net assets recognized for acquired businesses and represents future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is assigned to reporting units at the date the goodwill is initially recorded and is reallocated as necessary based on the composition of reporting units over time.
The Company assesses goodwill for impairment at the reporting unit level annually on the first day of the fourth quarter and upon the occurrence of a triggering event or change in circumstance that would more likely than not reduce the fair value of a reporting unit below its carrying amount.
A quantitative test performed upon the occurrence of a triggering event compares the fair value of a reporting unit with its carrying amount. The Company determines fair values for each of the reporting units, as applicable, using the market approach, when available and appropriate, or the income approach, or a combination of both. The Company assesses the valuation methodology based upon the relevance and availability of the data at the time the Company performs the valuation. If multiple valuation methodologies are used, the results are weighted appropriately.
Valuations using the market approach are derived from metrics of publicly traded companies or historically completed transactions of comparable businesses. The selection of comparable businesses is based on the markets in which the reporting units operate giving consideration to risk profiles, size, geography, and diversity of products and services. A market approach is limited to reporting units for which there are publicly traded companies that have characteristics similar to the Company’s businesses.
Under the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. The Company uses its internal forecasts to estimate future cash flows and include an
21
estimate of long-term future growth rates based on our most recent views of the long-term outlook for each business. Actual results may differ from those assumed in the forecasts. The Company derives its discount rates using a capital asset pricing model and by analyzing published rates for industries relevant to its reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in internally developed forecasts.
The following table shows changes in the carrying amount of goodwill by reportable segment as of September 30, 2026 and December 31, 2025 (in millions):
| Nuclear & Safety | Medical | Consolidated | |||||||||||||||
| Balance—December 31, 2025 | $ | $ | $ | ||||||||||||||
| Measurement period adjustments | ( | ( | |||||||||||||||
| Translation adjustment | ( | ( | |||||||||||||||
| Balance—September 30, 2026 | $ | $ | $ | ||||||||||||||
A portion of goodwill is deductible for income tax purposes.
Gross carrying amounts and cumulative goodwill impairment losses are as follows (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||||||||||||||
| Gross Carrying Amount | Cumulative Impairment | Gross Carrying Amount | Cumulative Impairment | ||||||||||||||||||||
| Goodwill | $ | $ | ( | $ | $ | ( | |||||||||||||||||
No triggering events for interim goodwill impairment testing occurred in the third quarter of 2026. However, the Company will continue to monitor macroeconomic conditions for future changes in assumptions or deterioration in market conditions, including impacts from rising long-term interest rates and geopolitical risks impacting global trade conditions, which could result in an impairment in one or more of the Company's reporting units. Our required annual goodwill impairment assessment for all reporting units will be performed during the fourth quarter of 2026.
Intangible Assets
Intangible assets primarily consist of our developed technology, customer relationships, remaining performance obligations, and trade names at the time of acquisition through business combinations. The customer relationships definite lived intangible assets are amortized either using the double declining balance method or on a straight-line basis, while all other definite lived intangible assets are amortized on a straight-line basis over their estimated useful lives.
22
Many of our intangible assets are not deductible for income tax purposes. A summary of intangible assets useful lives, gross carrying value and related accumulated amortization is below (in millions):
| September 30, 2026 | |||||||||||||||||||||||
| Original Average Life in Years | Gross Carrying Amount | Accumulated Amortization | Net Book Value | ||||||||||||||||||||
| Customer relationships | $ | $ | ( | $ | |||||||||||||||||||
| Distributor relationships | ( | ||||||||||||||||||||||
| Developed technology | ( | ||||||||||||||||||||||
| Trade names | ( | ||||||||||||||||||||||
| Remaining performance obligations and other | ( | ||||||||||||||||||||||
| Total | $ | $ | ( | $ | |||||||||||||||||||
| December 31, 2025 | |||||||||||||||||||||||
| Original Average Life in Years | Gross Carrying Amount | Accumulated Amortization | Net Book Value | ||||||||||||||||||||
| Customer relationships | $ | $ | ( | $ | |||||||||||||||||||
| Distributor relationships | ( | ||||||||||||||||||||||
| Developed technology | ( | ||||||||||||||||||||||
| Trade names | ( | ||||||||||||||||||||||
| Remaining performance obligations and other | ( | ||||||||||||||||||||||
| Total | $ | $ | ( | $ | |||||||||||||||||||
Aggregate amortization expense for intangible assets included in cost of revenues and operating expenses was as follows (in millions):
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Amortization expense for intangible assets in: | |||||||||||||||||||||||
| Cost of revenues | $ | $ | $ | $ | |||||||||||||||||||
| Operating expenses | $ | $ | $ | $ | |||||||||||||||||||
Estimated future amortization of intangible assets is as follows (in millions):
| Remainder of 2026 | $ | |||||||
| Year ending December 31: | ||||||||
| 2027 | ||||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 | ||||||||
| Thereafter | ||||||||
| Total | $ | |||||||
23
8. Borrowings
Debt (excluding convertible debt) consists of the following (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| 2021 Credit Agreement | $ | $ | |||||||||
| Other | |||||||||||
| Total debt | |||||||||||
| Less: debt, current | ( | ||||||||||
| Less: deferred financing costs | ( | ( | |||||||||
| Debt, non-current | $ | $ | |||||||||
As of September 30, 2026 and December 31, 2025, the fair market value of the Company’s outstanding principal borrowings under the 2021 Credit Agreement (defined below) was $451.1 million and $452.3 million, respectively. The fair market value for the 2021 Credit Agreement was estimated using primarily level 2 inputs, including borrowing rates available to the Company at the respective period ends. The fair market value for the Company’s remaining debt approximates the respective carrying amounts as of September 30, 2026 and December 31, 2025.
2021 Credit Agreement
The Company maintains a credit agreement (the “2021 Credit Agreement”) among Mirion IntermediateCo Inc., a Delaware corporation, as Holdings, Mirion Technologies (US Holdings), Inc., as the Parent Borrower, Mirion Technologies (US), Inc., as the Subsidiary Borrower, the lending institutions party thereto, and Citibank, N.A., as the Administrative Agent and Collateral Agent.
The 2021 Credit Agreement, as amended, provides for an $830.0 million senior secured first lien term loan facility and a $175.0 million senior secured revolving facility (collectively, the “Credit Facilities”). The term loan facility is scheduled to mature on June 5, 2032. The revolving facility is scheduled to expire and mature on March 21, 2030, subject to a “springing” maturity date that is 91 days prior to the maturity date of the outstanding term loan under the 2021 Credit Agreement (but only to the extent the outstanding principal amount of the term loan exceeds $100.0 million on the date of determination, and a final stated maturity date that is earlier than 91 days after March 21, 2030). The agreement requires the payment of a commitment fee of 0.50 % per annum for unused revolving commitments, subject to stepdowns to 0.375 % per annum and 0.25 % per annum upon the achievement of specified leverage ratios. Any outstanding letters of credit issued under the 2021 Credit Agreement reduce the availability under the revolving line of credit.
The 2021 Credit Agreement is secured by a first priority lien on the equity interests of the Parent Borrower owned by Holdings and substantially all of the assets (subject to customary exceptions) of the borrowers and the other guarantors thereunder. Interest with respect to the facilities is based on, at the option of the borrowers, (i) a customary base rate formula for borrowings in U.S. dollars or (ii) a floating rate formula based on the Secured Overnight Financing Rate (“SOFR”) for borrowings in U.S. dollars, a floating rate formula based on Euro Interbank Offered Rate (“EURIBOR”) for borrowings in Euro or a floating rate formula based on the Sterling Overnight Index Average (“SONIA”) for borrowings in Pounds Sterling, each as described in the 2021 Credit Agreement with respect to the applicable type of borrowing.
The 2021 Credit Agreement contains customary representations and warranties as well as customary affirmative and negative covenants and events of default. The negative covenants include, among others and in each case subject to certain thresholds and exceptions, limitations on incurrence of liens, limitations on incurrence of indebtedness, limitations on making dividends and other distributions, limitations on engaging in asset sales, limitations on making investments, and a financial covenant that the “First Lien Net Leverage Ratio” (as defined in the 2021 Credit Agreement) as of the end of any fiscal quarter is not greater than 7.00 to 1.00 if on the last day of such fiscal quarter certain borrowings outstanding under the revolving credit facility exceed 40 % of the total revolving credit commitments at such time. The covenants also contain limitations on the activities of Mirion IntermediateCo, Inc. as the “passive” holding company. If any of the events of default occur and are not cured or waived, any unpaid amounts under the 2021 Credit Agreement may be declared immediately due and payable, the revolving credit commitments may be terminated and remedies against the collateral may be exercised. Mirion IntermediateCo, Inc. was in compliance with all debt covenants on September 30, 2026 and December 31, 2025.
24
The interest rate on the term loan was 5.73 % and 5.78 % as of September 30, 2026 and December 31, 2025, respectively, based on the greater of SOFR or 0.50 %, and the applicable margin rate of 2.00 %. The Company had no repayments during the nine months ended September 30, 2026, and repaid $244.6 million during the twelve months ended December 31, 2025.
The 2021 Credit Agreement requires the payment of a commitment fee of 0.25 % per annum for unused commitments. Any outstanding letters of credit reduce the availability of the revolving line of credit. There was no 12.9 million and $15.7 million for the periods ended September 30, 2026 and December 31, 2025, respectively. The amount available on the revolver as of September 30, 2026 and December 31, 2025 was approximately $162.1 million and $159.3 million, respectively.
Deferred Financing Costs
In accordance with accounting for debt issuance costs, we recognize and present deferred finance costs associated with non-revolving debt and financing obligations as a reduction from the face amount of related indebtedness in the unaudited Condensed Consolidated Balance Sheets. We recognize and present debt issuance costs associated with revolving debt arrangements as an asset and include the deferred finance costs within other assets in the unaudited Condensed Consolidated Balance Sheets. We amortize all debt issuance costs over the life of the related indebtedness.
For the three and nine months ended September 30, 2026, we incurred approximately $0.3 million and $1.1 million, of amortization expense of the deferred financing costs, respectively, relating to the term loan facility and the revolving facility. For the three and nine months ended September 30, 2025, we incurred approximately $0.9 million and $8.5 million (inclusive of a $5.8 244.6
Overdraft Facilities
The Company has overdraft facilities with certain German and French financial institutions. As of September 30, 2026 and December 31, 2025, there were no
Accounts Receivable Sales Agreement
We are party to agreements to sell short-term receivables from certain qualified customer trade accounts to an unaffiliated French financial institution and an unaffiliated Finnish financial institution without recourse. Under these agreements, the Company can sell up to €10.0 million ($11.4 million) and €12.4 million ($14.6 million) as of September 30, 2026 and December 31, 2025, respectively, of eligible accounts receivables. The accounts receivable under these agreements are sold at face value and are excluded from the consolidated balance if revenue has been recognized on the related receivable. When the related revenue has not been recognized on the receivable the Company considers the accounts receivable to be collateral for short-term borrowings. As of September 30, 2026 and December 31, 2025, there was no balance for both periods outstanding under these arrangements included as Other in the Borrowings table above.
Total costs associated with this arrangement were immaterial for all periods presented and are included in selling, general and administrative expenses in the unaudited Condensed Consolidated Statements of Operations.
Performance Bonds and Other Credit Facilities
The Company has entered into various line of credit arrangements with local banks in France and Germany. These arrangements provide for the issuance of documentary and standby letters of credit of up to €69.7 million ($77.5 million) and €73.5 million ($85.4 million), as of September 30, 2026 and December 31, 2025, respectively, subject to certain local restrictions. As of September 30, 2026 and December 31, 2025, there were €32.9 million ($37.5 million) and €37.3 million ($43.9 million), respectively, of the lines that had been utilized to guarantee documentary and standby letters of credit, with interest rates ranging from 0.5 % to 2.0 %. In addition, the Company posts performance bonds with irrevocable letters of credit to support certain contractual obligations to customers for equipment delivery. These letters of credit are supported by restricted cash accounts, which totaled $2.9
25
At September 30, 2026, contractual principal payments of total borrowings are as follows (in millions):
| Remainder of 2026 | $ | ||||
| Year ending December 31: | |||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| 2030 | |||||
| Thereafter | |||||
| Gross Payments | |||||
| Unamortized debt issuance costs | ( | ||||
| Total borrowings, net of debt issuance costs | $ | ||||
9. Convertible Debt
Convertible debt consists of the following (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| 2030 notes | $ | $ | |||||||||
| 2031 notes | |||||||||||
| Total convertible debt | |||||||||||
| Less: deferred financing costs | ( | ( | |||||||||
| Convertible debt | $ | $ | |||||||||
Convertible Senior Notes due 2030
On May 23, 2025, the Company completed a private offering of $400.0 million in aggregate principal amount of 0.25 % Convertible Senior Notes due 2030, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2030 Notes”). The 2030 Notes were issued pursuant to an indenture, dated May 23, 2025 (the “Indenture”). The Indenture includes customary covenants and sets forth certain events of default after which the 2030 Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the outstanding principal and accrued interest of the 2030 Notes becomes automatically due and payable.
The 2030 Notes will mature on June 1, 2030, unless earlier converted, redeemed or repurchased. The 2030 Notes will bear interest from May 23, 2025 at a rate of 0.25 % per year payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2025. The 2030 Notes will be convertible at the option of the holders in certain circumstances discussed below. The 2030 Notes will be convertible into cash, shares of Mirion’s Class A common stock or a combination of cash and shares of Mirion’s Class A common stock, at the Company’s election.
The initial conversion rate is 43.2751 shares of Mirion’s Class A common stock per $1,000 principal amount of 2030 Notes, which is equivalent to an initial conversion price of approximately $23.11 per share of Mirion's Class A common stock. The initial conversion price of the 2030 Notes represents a conversion premium of 32.5 % to the last reported sale price of Mirion’s Class A common stock of $17.44 per share on May 20, 2025. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.
The Company may not redeem the 2030 Notes prior to June 6, 2028. The Company may redeem for cash 100 % of the principal amount of the 2030 Notes being redeemed plus accrued and unpaid interest or any portion of the 2030 Notes, at its option, on or after June 6, 2028, but only if a certain liquidity condition has been satisfied and the last reported sale price of Mirion's Class A common stock has been at least 130 % of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period. If the Company redeems less than all of the outstanding 2030 Notes, at least $100.0 million aggregate principal amount of 2030 Notes must be outstanding and not subject to redemption as of, and after giving effect to, delivery of the relevant redemption notice.
26
The 2030 Notes are convertible by holders on or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date, but can only be early exercised under the following circumstances:
•During any calendar quarter after September 30, 2025 (and only during such calendar quarter) if the closing price of the Company's common stock for at least 20 trading days in a period of 30 consecutive trading days ending on and including the last trading day of the preceding calendar quarter is more than 130 % of the then applicable conversion price for the 2030 Notes per share of common stock.
•During the five business days immediately after any ten consecutive trading day period in which the trading price per $1,000 principal amount of 2030 Notes, as determined following a request by a holder of 2030 Notes, for each day of that period was less than 98 % of the product of the closing price of our common stock and the then applicable conversion rate.
•If the Company calls any or all of the 2030 Notes for redemption, holders may convert all or any portion of their 2030 Notes at any time prior to the close of business on the scheduled trading day prior to the redemption date, even if the 2030 Notes are not otherwise convertible at such time.
•If specified distributions to holders of our common stock are made or specified corporate events occur.
If the Company undergoes a fundamental change, as defined in the Indenture, then subject to certain conditions and limited exceptions, holders may require the Company to repurchase for cash all or any portion of their 2030 Notes in principal amounts of $1,000 or an integral multiple thereof at a repurchase price equal to 100 % of the principal amount of the 2030 Notes to be repurchased plus accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity date or if the Company issues a notice a redemption, the Company will increase the conversion rate for holders who elect to convert their 2030 Notes in connection with such a corporate event. The conditions allowing holders of the 2030 Notes to convert were not met during the three and nine months ended September 30, 2026.
Convertible Senior Notes due 2031
On September 30, 2025, concurrently with an offering of Mirion's Class A common stock, the Company completed a private offering of $375.0 million in aggregate principal amount of 0.00 % Convertible Senior Notes due 2031, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2031 Notes”). The Company used the net proceeds from these transactions to consummate a purchase of all of the outstanding membership interests of WCI-Gigawatt Intermediate Holdco, LLC, as the indirect parent of Paragon Energy Solutions, LLC, for $588.6 million pursuant to the equity purchase agreement signed September 24, 2025. The acquisition closed on December 1, 2025. Refer to Note 2, Business Combinations, Acquisitions, and Business Disposals, for additional information.
The 2031 Notes were issued pursuant to an indenture, dated September 30, 2025 (the “September Indenture”). The September Indenture includes customary covenants and sets forth certain events of default after which the 2031 Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the outstanding principal and any unpaid special interest of the 2031 Notes becomes automatically due and payable.
The 2031 Notes will mature on October 1, 2031, unless earlier converted, redeemed or repurchased. The 2031 Notes will not bear regular interest, and the principal amount of the 2031 Notes will not accrete. Special interest will accrue on the 2031 Notes in the circumstances at the rates set forth within the September Indenture. The 2031 Notes will be convertible at the option of the holders in certain circumstances discussed below. The 2031 Notes will be convertible into cash, shares of Mirion’s Class A common stock or a combination of cash and shares of Mirion’s Class A common stock, at the Company’s election.
The initial conversion rate is 34.6951 shares of Mirion’s Class A common stock per $1,000 principal amount of 2031 Notes, which is equivalent to an initial conversion price of approximately $28.82 per share of Mirion's Class A common stock. The initial conversion price of the 2031 Notes represents a conversion premium of 35.0 % to the related public offering price per share of Mirion Class A common stock of $21.35 per share. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the September Indenture.
The Company may not redeem the 2031 Notes prior to October 5, 2028. The Company may redeem for cash 100 % of the principal amount of the 2031 Notes being redeemed plus any unpaid special interest or any portion of the 2031 Notes, at its option, on or after October 5, 2028, but only if a certain liquidity condition has been satisfied and the last reported sale price of Mirion's Class A common stock has been at least 130 % of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period. If the Company redeems less than all of the outstanding 2031 Notes, at least $100.0 million aggregate principal amount of the 2031 Notes must be outstanding and not subject to redemption as of, and after giving effect to, delivery of the relevant redemption notice.
27
The 2031 Notes are convertible by holders on or after July 1, 2031 until the close of business on the second scheduled trading day immediately preceding the maturity date, but can only be early exercised under the following circumstances:
•During any calendar quarter after December 31, 2025 (and only during such calendar quarter) if the closing price of the Company's common stock for at least 20 trading days in a period of 30 consecutive trading days ending on and including the last trading day of the preceding calendar quarter is more than 130 % of the then applicable conversion price for the 2031 Notes per share of common stock.
•During the five business days immediately after any ten consecutive trading day period in which the trading price per $1,000 principal amount of 2031 Notes, as determined following a request by a holder of 2031 Notes, for each day of that period was less than 98 % of the product of the closing price of our common stock and the then applicable conversion rate.
•If the Company calls any or all of the 2031 Notes for redemption, holders may convert all or any portion of their 2031 Notes at any time prior to the close of business on the scheduled trading day prior to the redemption date, even if the 2031 Notes are not otherwise convertible at such time.
•If specified distributions to holders of our common stock are made or specified corporate events occur.
If the Company undergoes a fundamental change at any point, as defined in the September Indenture, then subject to certain conditions and limited exceptions, holders may require the Company to repurchase for cash all or any portion of their 2031 Notes in principal amounts of $1,000 or an integral multiple thereof at a repurchase price equal to 100 % of the principal amount of the 2031 Notes to be repurchased plus any unpaid special interest. In addition, if specific corporate events occur prior to the maturity date or if the Company issues a notice of redemption, the Company will increase the conversion rate for holders who elect to convert their 2031 Notes in connection with such a corporate event. The conditions allowing holders of the 2031 Notes to convert were not met during the three and nine months ended September 30, 2026.
Interest and Maturity
The 2030 Notes and 2031 Notes are classified as long-term liabilities, net of issuance costs of $9.1 million and $8.3 million, respectively, as of September 30, 2026, and $12.4 million and $9.9 million, respectively, as of December 31, 2025, on the unaudited Condensed Consolidated Balance Sheets. As of September 30, 2026 and December 31, 2025, the net carrying amount of the 2030 Notes and 2031 Notes approximates fair value. As the 2030 Notes and 2031 Notes were not issued at a premium, no portion of the proceeds from the issuance of the 2030 Notes and 2031 Notes met the requirements to be accounted for separately as a component of stockholders’ equity. The 2030 Notes and 2031 Notes were issued at par, and costs associated with the issuance of the 2030 Notes and 2031 Notes are amortized to interest expense over the contractual term of the respective Notes. Interest expense (including amortization of deferred issuance costs) recognized related to the 2030 Notes for the three and nine months ended September 30, 2026 was $0.9 million and $2.6 million, respectively and $0.9 million and $1.3 million for the three and nine months ended September 30, 2025, respectively. No special interest was recorded for the 2031 Notes and amortization of deferred financing costs of $0.4 million and $1.2 million was recorded for the 2031 Notes during the three and nine months ended September 30, 2026. As of September 30, 2026, the effective interest rate of the 2030 Notes is 0.88 %.
At September 30, 2026, future maturities of the Notes are as follows (in millions):
| Remainder of 2026 | $ | ||||
| Year ending December 31: | |||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| 2030 | |||||
| Thereafter | |||||
| $ | |||||
Capped Call Transactions
In May 2025, subsequent to the pricing of the 2030 Notes, the Company entered into privately negotiated capped call transactions (the “May Capped Call Transactions”). The May Capped Call Transactions initially cover, subject to customary anti-dilution adjustments substantially similar to those applicable to the 2030 Notes, the number of shares of Mirion’s Class A common stock that underlie the 2030 Notes for the purpose of limiting the potentially dilutive impacts of the 2030 Notes. The cap price of the May Capped Call Transactions is initially $34.88 per share, which represents a
28
premium of 100 % over the last reported sale price of Mirion’s Class A common stock of $17.44 per share on May 20, 2025, and is subject to certain adjustments under the terms of the May Capped Call Transactions. The initial strike price of the May Capped Call Transactions is equal to the initial conversion price of the 2030 Notes. The default settlement method is net share settlement; however, the Company may elect to settle the May Capped Call Transactions in cash. The Company used $44.6 million of the proceeds from the offering of 2030 Notes to pay the cost of the May Capped Call Transactions.
In September 2025, in connection with the pricing of the 2031 Notes, the Company entered into privately negotiated capped call transactions (the "September Capped Call Transactions"). The September Capped Call Transactions initially cover, subject to customary anti-dilution adjustments substantially similar to those applicable to the 2031 Notes, the number of shares of Mirion's Class A common stock that underlie the 2031 Notes for the purpose of limiting the potentially dilutive impacts of the 2031 Notes. The cap price of the September Capped Call Transactions is initially $42.70 per share, which represents a premium of 100 % over the related public offering price per share of Mirion Class A common stock of $21.35 , and is subject to certain adjustments under the terms of the September Capped Call Transactions. The initial strike price of the September Capped Call Transactions is equal to the initial conversion price of the 2031 Notes. The default settlement method is net share settlement; however, the Company may elect to settle the September Capped Call Transactions in cash. The Company used $38.0 million of the proceeds from the offering of the 2031 Notes to pay the cost of the September Capped Call Transactions.
The Company evaluated the May and September Capped Call Transactions and determined that they should be accounted as separate transactions from the 2030 Notes and 2031 Notes, respectively. The costs of $44.6 million to purchase the May Capped Call Transactions and $38.0 million to purchase the September Capped Call Transactions were recorded as a reduction to additional paid-in capital in the unaudited Condensed Consolidated Balance Sheets during the year ended December 31, 2025, with no changes in the three and nine months ended September 30, 2026 since they are indexed to the Company’s stock and met the criteria to be classified in stockholders' equity in accordance with ASC 815-40, "Contracts in Entity's Own Equity".
10. Leased Assets
The Company primarily leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally 1 to 10 years). The exercise of lease renewal options is at the Company’s discretion. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants.
The table below presents the locations of the operating lease assets and liabilities in the unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025, respectively (in millions):
| Balance Sheet Line Item | September 30, 2026 | December 31, 2025 | |||||||||||||||
| Operating lease assets | Operating lease right-of-use assets | $ | $ | ||||||||||||||
| Operating lease liabilities: | |||||||||||||||||
| Current operating lease liabilities | Operating lease liabilities, current | $ | $ | ||||||||||||||
| Non-current operating lease liabilities | Operating lease liabilities, non-current | ||||||||||||||||
| Total operating lease liabilities: | $ | $ | |||||||||||||||
The depreciable lives are limited by the expected lease term for operating lease assets and by the shorter of either the expected lease term or the economic useful life for financing lease assets.
The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment.
29
The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of September 30, 2026 and December 31, 2025, respectively, are:
| September 30, 2026 | December 31, 2025 | |||||||||||||
| Operating leases | ||||||||||||||
| Weighted average remaining lease term (in years) | ||||||||||||||
| Weighted average discount rate | % | % | ||||||||||||
The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancelable operating leases with terms of more than one year to the total lease liabilities recognized in the unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 (in millions):
| Year ending December 31: | |||||
| 2026 | $ | ||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| 2030 | |||||
| Thereafter | |||||
| Total undiscounted future minimum lease payments | |||||
| Less: Imputed interest | ( | ||||
| Total operating lease liabilities | $ | ||||
For the three and nine months ended September 30, 2026, operating lease costs (as defined under ASU 2016-02) were $3.2 million and $7.8 million, respectively, and for the three and nine months ended September 30, 2025 operating lease costs were $2.6 million and $6.8 million respectively. Operating lease costs are included within costs of goods sold, selling, general and administrative, and research and development expenses on the unaudited Condensed Consolidated Statements of Operations. Short-term lease costs, variable lease costs and sublease income were not material for the periods presented.
Cash paid for amounts included in the measurement of operating lease liabilities was $7.9 million for the nine months ended September 30, 2026 and $7.0 million for nine months ended September 30, 2025, and these amounts are included in operating activities in the unaudited Condensed Consolidated Statements of Cash Flows. There were $13.9 million of non-cash operating lease assets obtained in exchange for new operating lease liabilities for the three months ended September 30, 2026 and $14.8 million for the nine months ended September 30, 2026, respectively, and $1.9 million and $4.4 million for the three and nine months ended September 30, 2025, respectively.
11. Commitments and Contingencies
Unconditional Purchase Obligations
The Company has entered into certain long-term unconditional purchase obligations with suppliers. These agreements are non-cancellable and specify terms, including fixed or minimum quantities to be purchased, fixed or variable price provisions, and the approximate timing of payment. As of September 30, 2026, unconditional purchase obligations were as follows (in millions):
| Year ending December 31: | |||||
| 2026 | $ | ||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| 2030 and thereafter | |||||
| Total | $ | ||||
30
Litigation
The Company is subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. While the ultimate results of such suits or other proceedings against the Company cannot be predicted with certainty, we believe the resolution of these matters will not have a material effect on our results of operations, financial condition, or cash flows. If we believe the likelihood of an adverse legal outcome is probable and the amount is reasonably estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company.
In April 2023, one of our Russian customers made a claim against the Company, including liquidated damages for certain delays under the terms of an active project, in the amount of $19.3 million, and sent an updated claim statement in October 2023 totaling $21 million ($18 million of which accrue daily penalties), subject to a $14 million contractual cap (all amounts converted from Euros to U.S. Dollars). In November 2024, the Company reached an agreement to modify the underlying contract and the claim was fully rescinded by the customer. This agreement was fully executed in March 2026 after the obtainment of customary performance guarantees (which had been previously delayed due to certain Russian sanctions). The fully executed agreement did not have a material impact to our financial statements.
12. Income Taxes
The effective income tax rate was 28.4 % and 26.5 % for the three and nine months ended September 30, 2026, respectively, and (158.3 )% and (25.0 )% for the three and nine months ended September 30, 2025, respectively. The difference in effective tax rate between the periods was primarily attributable to mix of earnings.
The effective income tax rate differs from the U.S. statutory rate of 21% due primarily to U.S. federal income tax permanent differences and the impact of valuation allowances.
Many countries have incorporated Pillar Two global minimum tax rules into their domestic laws. Pillar Two legislation was effective for the Company for the year ended December 31, 2025. For the three and nine months ended September 30, 2026, there was no impact from Pillar Two on our unaudited condensed consolidated financial statements.
31
13. Supplemental Disclosures to Condensed Consolidated Statements of Cash Flows
Supplemental cash flow information and schedules of non-cash investing and financing activities (in millions):
| Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||
| Cash Paid For: | |||||||||||
| Cash paid for interest | $ | $ | |||||||||
| Cash paid for income taxes | $ | $ | |||||||||
| Non-Cash Investing and Financing Activities: | |||||||||||
| Property, plant, and equipment purchases in accrued expenses and other liabilities | $ | $ | |||||||||
| Property, plant, and equipment purchases in accounts payable | $ | $ | |||||||||
| Excise tax on purchases of treasury stock in accrued expenses and other liabilities | $ | $ | |||||||||
| Convertible debt issuance costs in accrued expenses and other liabilities | $ | $ | |||||||||
| Common stock issuance costs in accrued expenses and other liabilities | $ | $ | |||||||||
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited Condensed Consolidated Balances Sheets that sum to the total of the same such amounts shown in the unaudited Condensed Consolidated Statements of Cash Flows (in millions).
| September 30, 2026 | December 31, 2025 | ||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Restricted cash—current (included within prepaid expenses and other current assets) | |||||||||||
| Restricted cash—non-current (included within other assets) | |||||||||||
| Total cash, cash equivalents, and restricted cash | $ | $ | |||||||||
Amounts included in restricted cash represent funds with various financial institutions to support performance bonds with irrevocable letters of credit for contractual obligations to certain customers.
14. Stock-Based Compensation
Stock-based compensation is awarded to employees and directors of the Company and accounted for in accordance with ASC 718, “Compensation—Stock Compensation”. Stock-based compensation expense is recognized for equity awards over the vesting period based on their grant-date fair value. Stock-based compensation expense is included within the same financial statement caption where the recipient’s other compensation is reported. The Company accounts for forfeitures as they occur. The Company uses various forms of long-term incentives including, but not limited to, restricted stock units (“RSUs”), performance-based restricted units (“PSUs”), and performance vesting stock options (“PSOs”), provided that the granting of such equity awards is in accordance with the Company’s 2021 Omnibus Incentive Plan (the “2021 Plan”) as filed on Form S-8 with the SEC on December 27, 2021.
32
2021 Omnibus Incentive Plan
We adopted and obtained stockholder approval at the special meeting of the stockholders on October 19, 2021 of the 2021 Plan. We initially reserved 19,952,329 shares of our Class A common stock for issuance pursuant to awards under the 2021 Plan. The total number of shares of our Class A common stock available for issuance under the 2021 Plan will be increased on the first day of each fiscal year following the date on which the 2021 Plan was adopted in an amount equal to the least of (i) three percent (3 %) of the outstanding shares of Class A common stock on the last day of the immediately preceding fiscal year, (ii) 9,976,164 shares of Class A common stock and (iii) such number of shares of Class A common stock as determined by the Committee (as defined and designated under the 2021 Plan) in its discretion. Pursuant to these automatic increase provisions, the number of shares of our Class A common stock reserved for issuance pursuant to awards under the 2021 Plan increased to 52,609,685 shares at January 1, 2026 (excluding the impact of grants and forfeitures plan to date). Any employee, director or consultant of the Company or any of its subsidiaries or affiliates is eligible to receive an award under the 2021 Plan, to the extent that an offer of such award is permitted by applicable law, stock market or exchange rules, and regulations or accounting or tax rules and regulations. The 2021 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, PSUs, other stock-based awards, or any combination thereof. Each award will be set forth in a separate grant notice or agreement and will indicate the type and terms and conditions of the award.
The purpose of the 2021 Plan is to motivate and reward employees and other individuals to perform at their highest level and contribute significantly to the success of the Company. During the three months ended September 30, 2026, the Company granted 20,790 RSUs to certain employees. The RSUs granted to employees are subject to terms consistent with grants made in the prior quarter. The expense will be recognized on a straight-line basis over the related service period for each tranche of awards.
During the three months ended September 30, 2025, the Company granted 217,539 RSUs and 1,219 PSUs to certain employees. The RSUs granted to employees are subject to service vesting conditions such that all awards are fully vested after three (3 ) or five (5 ) years with equal annual installments vesting on the anniversary of the grant date. The expense will be recognized on a straight-line basis over the related service period for each tranche of awards. The PSUs vest over a three (3) year performance period beginning on January 1 of the grant year and are subject to service and performance/market vesting conditions.
15. Segment Information
The Company manages its operations through two
Description of Segments
The Nuclear & Safety segment provides radiation detection equipment for power plants, labs and research facilities and industrial and defense applications. Nuclear products are concentrated in power plant product offerings that are used for the full nuclear power plant lifecycle including core detectors and essential measurement devices for new build, maintenance, decontamination and decommission equipment for monitoring and control during fuel dismantling, and remote environmental monitoring. Labs and research and other (primarily industrial and defense) are focused on the area of personal radiation detection for various safety and security requirements.
The Medical segment provides solutions focused on ensuring safety of equipment and personnel in the medical field. The primary product category relates to Cancer Care applications, including radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world, radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy, and radionuclide therapy products for nuclear medicine applications such as product handling and medical imaging furniture. Other Medical segment products include dosimetry solutions for monitoring the total amount of radiation medical staff members are exposed to over time.
33
The CODM evaluates operating results and allocates capital resources between segments based on segment operating income (loss). Interest income and expense, loss (benefit) from income taxes, foreign currency loss (gain), net, other expense (income), net, and, if applicable, other items such as loss on debt extinguishment, are not allocated to segments.
The following tables summarize information about revenue, significant segment expenses, other segment items, and segment income (loss) from operations for each reportable segment (in millions). Reconciliation of consolidated segment income (loss) from operations to consolidated income before income taxes is shown in the Total column of each table.
| Three Months Ended September 30, 2026 | |||||||||||||||||
| Nuclear & Safety | Medical | Total | |||||||||||||||
| Revenues | $ | $ | $ | ||||||||||||||
| Less: | |||||||||||||||||
Adjusted cost of revenues (1) | |||||||||||||||||
Other segment items (2) | |||||||||||||||||
| Segment income from operations | $ | $ | $ | ||||||||||||||
Other loss (3) | ( | ||||||||||||||||
| Income from operations | |||||||||||||||||
| Less other expense (income): | |||||||||||||||||
| Interest expense | |||||||||||||||||
| Interest income | ( | ||||||||||||||||
| Foreign currency loss, net | |||||||||||||||||
| Other expense, net | |||||||||||||||||
| Consolidated income before income taxes | $ | ||||||||||||||||
| Three Months Ended September 30, 2025 | |||||||||||||||||
| Nuclear & Safety | Medical | Total | |||||||||||||||
| Revenues | $ | $ | $ | ||||||||||||||
| Less: | |||||||||||||||||
Adjusted cost of revenues (1) | |||||||||||||||||
Other segment items (2) | |||||||||||||||||
| Segment income from operations | $ | $ | $ | ||||||||||||||
Other loss (3) | ( | ||||||||||||||||
| Income from operations | |||||||||||||||||
| Less other expense (income): | |||||||||||||||||
| Interest expense | |||||||||||||||||
| Interest income | ( | ||||||||||||||||
| Foreign currency gain, net | ( | ||||||||||||||||
| Other expense, net | |||||||||||||||||
| Consolidated income before income taxes | $ | ||||||||||||||||
34
| Nine Months Ended September 30, 2026 | |||||||||||||||||
| Nuclear & Safety | Medical | Total | |||||||||||||||
| Revenues | $ | $ | $ | ||||||||||||||
| Less: | |||||||||||||||||
Adjusted cost of revenues (1) | |||||||||||||||||
Other segment items (2) | |||||||||||||||||
| Segment income from operations | $ | $ | $ | ||||||||||||||
Other loss (3) | ( | ||||||||||||||||
| Income from operations | |||||||||||||||||
| Less other expense (income): | |||||||||||||||||
| Interest expense | |||||||||||||||||
| Interest income | ( | ||||||||||||||||
| Foreign currency loss, net | |||||||||||||||||
| Other expense, net | |||||||||||||||||
| Consolidated income before income taxes | $ | ||||||||||||||||
| Nine Months Ended September 30, 2025 | |||||||||||||||||
| Nuclear & Safety | Medical | Total | |||||||||||||||
| Revenues | $ | $ | $ | ||||||||||||||
| Less: | |||||||||||||||||
Adjusted cost of revenues (1) | |||||||||||||||||
Other segment items (2) | |||||||||||||||||
| Segment income from operations | $ | $ | $ | ||||||||||||||
Other loss (3) | ( | ||||||||||||||||
| Income from operations | |||||||||||||||||
| Less other expense (income): | |||||||||||||||||
| Interest expense | |||||||||||||||||
| Interest income | ( | ||||||||||||||||
| Loss on debt extinguishment | |||||||||||||||||
| Foreign currency gain, net | ( | ||||||||||||||||
| Other expense, net | |||||||||||||||||
| Consolidated income before income taxes | $ | ||||||||||||||||
(1) Adjusted cost of revenues is a significant expense category, and amounts align with the segment-level information that is regularly provided to the CODM. Adjusted cost of revenues is defined by management as cost of revenues adjusted for purchase accounting impacts and excluding depreciation, amortization, and other segment expenses identified as non-operating by management.
(2) Other segment items included in segment income (loss) from operations for each segment include research and development expenses; selling and marketing expenses; general and administrative expenses; and any amounts excluded from cost of revenues to determine adjusted costs of revenues (e.g., depreciation, amortization, and other segment expenses identified as non-operating by management).
(3)Other loss consists of research and development expenses; selling and marketing expenses; and general and administrative expenses not allocated to the segments.
35
The following table summarizes capital expenditures and depreciation and amortization for each reportable segment (in millions):
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Capital expenditures | |||||||||||||||||||||||
| Nuclear & Safety | $ | $ | $ | $ | |||||||||||||||||||
| Medical | |||||||||||||||||||||||
| Total operating and reportable segments | |||||||||||||||||||||||
| Corporate and other | |||||||||||||||||||||||
| Total capital expenditures | $ | $ | $ | $ | |||||||||||||||||||
| Depreciation and amortization | |||||||||||||||||||||||
| Nuclear & Safety | $ | $ | $ | $ | |||||||||||||||||||
| Medical | |||||||||||||||||||||||
| Total operating and reportable segments | |||||||||||||||||||||||
| Corporate and other | |||||||||||||||||||||||
| Total depreciation and amortization | $ | $ | $ | $ | |||||||||||||||||||
The Company’s assets by reportable segment were not included, as this information is not reviewed by, nor otherwise provided to, the chief operating decision maker to make operating decisions or allocate resources.
The following details revenues by geographic region. Revenues generated from external customers are attributed to geographic regions through sales from site locations (i.e., point of origin) (in millions).
| Revenues | |||||||||||||||||||||||
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| North America | |||||||||||||||||||||||
| Nuclear & Safety | $ | $ | $ | $ | |||||||||||||||||||
| Medical | |||||||||||||||||||||||
| Total North America | |||||||||||||||||||||||
| Europe | |||||||||||||||||||||||
| Nuclear & Safety | |||||||||||||||||||||||
| Medical | |||||||||||||||||||||||
| Total Europe | |||||||||||||||||||||||
| Asia Pacific | |||||||||||||||||||||||
| Nuclear & Safety | |||||||||||||||||||||||
| Medical | |||||||||||||||||||||||
| Total Asia Pacific | |||||||||||||||||||||||
| Total Revenues | $ | $ | $ | $ | |||||||||||||||||||
36
The following details revenues by product for each segment (in millions):
| Revenues | |||||||||||||||||||||||
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Nuclear & Safety segment: | |||||||||||||||||||||||
| Nuclear | $ | $ | $ | $ | |||||||||||||||||||
| Labs and research | |||||||||||||||||||||||
| Other | |||||||||||||||||||||||
| Medical segment: | |||||||||||||||||||||||
| Cancer care | |||||||||||||||||||||||
| Other medical | |||||||||||||||||||||||
| Total Revenues | $ | $ | $ | $ | |||||||||||||||||||
The following details revenues by timing of recognition (in millions):
| Revenues | |||||||||||||||||||||||
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Point in time | $ | $ | $ | $ | |||||||||||||||||||
| Over time | |||||||||||||||||||||||
| Total revenues | $ | $ | $ | $ | |||||||||||||||||||
The following details property, plant, and equipment, net, by geography (in millions):
| Property, Plant, and Equipment, Net | |||||||||||
| September 30, 2026 | December 31, 2025 | ||||||||||
| North America | $ | $ | |||||||||
| Europe | |||||||||||
| Asia Pacific | |||||||||||
| Total | $ | $ | |||||||||
16. Fair Value Measurements
The Company applies fair value accounting to all financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. The fair value of the Company’s cash and cash equivalents, restricted cash, accounts receivable, and other current assets and liabilities approximates their carrying amounts due to the relatively short maturity of these items. The fair value of debt approximates the carrying value because the interest rates are variable and reflect market rates.
Fair Value of Financial Instruments
The Company categorizes assets and liabilities recorded at fair value in the unaudited Condensed Consolidated Balance Sheets based upon the level of judgment associated with inputs used to measure their fair value. It is not practicable due to cost and effort for the Company to estimate the fair value of notes issued to related parties primarily due to the nature of their terms relative to the entity’s capital structure.
Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy:
Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 – Inputs are quoted prices in active markets for similar assets or liabilities or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
37
Level 3 – Inputs are unobservable and require significant management judgment or estimation.
The following table summarizes the financial assets and liabilities of the Company that are measured at fair value on a recurring basis (in millions):
Fair Value Measurements at September 30, 2026 | |||||||||||||||||
| Level 1 | Level 2 | Level 3 | |||||||||||||||
| Assets | |||||||||||||||||
| Cash, cash equivalents, and restricted cash (Note 13) | $ | $ | $ | ||||||||||||||
| Discretionary retirement plan | $ | $ | $ | ||||||||||||||
| Accrued interest receivable on interest-rate swaps (Note 17) | $ | $ | $ | ||||||||||||||
| Interest rate swaps (Note 17) | $ | $ | $ | ||||||||||||||
| Liabilities | |||||||||||||||||
| Discretionary retirement plan | $ | $ | $ | ||||||||||||||
| Cross-currency rate swaps (Note 17) | $ | $ | $ | ||||||||||||||
Fair Value Measurements at December 31, 2025 | |||||||||||||||||
| Level 1 | Level 2 | Level 3 | |||||||||||||||
| Assets | |||||||||||||||||
| Cash, cash equivalents, and restricted cash (Note 13) | $ | $ | $ | ||||||||||||||
| Discretionary retirement plan | $ | $ | $ | ||||||||||||||
| Accrued interest receivable on cross-currency swaps (Note 17) | $ | $ | $ | ||||||||||||||
| Liabilities | |||||||||||||||||
| Discretionary retirement plan | $ | $ | $ | ||||||||||||||
| Interest rate swap (Note 17) | $ | $ | $ | ||||||||||||||
| Cross-currency rate swaps (Note 17) | $ | $ | $ | ||||||||||||||
Cash equivalents include investments in money market funds which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance.
The cross-currency rate swaps and the interest rate swaps are not exchange traded instruments, and their fair value is determined using the cash flows of the swap contracts, discount rates to account for the passage of time, current foreign exchange market data, current interest rate (SOFR) data, and credit risk, which are all based on inputs readily available in public markets and categorized as Level 2 fair value hierarchy measurements.
38
17. Derivatives and Hedging
The Company’s policy requires derivatives to be used solely for managing risks and not for speculative purposes. As a result of the Company’s European operations, the Company is exposed to fluctuations in exchange rates between EUR and USD. As such, the Company entered into two cross-currency rate swaps during the year ended December 31, 2022, to manage currency risks related to our investments in foreign operations. During the year ended December 31, 2025, the Company extended one cross-currency rate swap derivative by 2 years. During the nine months ended September 30, 2026, the Company extended the other cross-currency rate swap derivative by thirty-three months. The Company is also subject to interest rate risk related to the Credit Facilities. The Company manages its risk to interest rate fluctuations through the use of derivative financial instruments. As such, the Company entered into an interest rate swap (notional amount of $75.0 million) during the year ended December 31, 2023 (settled during the three months ended June 30, 2026), as well as an additional interest rate swap (notional amount of $100.0 million) during the year ended December 31, 2025 (scheduled to settle during the fourth quarter of 2026), to mitigate the risk of adverse changes in benchmark interest rates on the Company’s future interest payments (collectively, the “interest rate swaps”).
All derivative instruments are carried at fair value in the unaudited Condensed Consolidated Balance Sheets. The following table presents the fair values of the Company’s derivative instruments that were designated and qualified as part of a hedging relationship (in millions):
Fair Value (1) | ||||||||||||||||||||
| Derivatives Designated as Hedging Instruments | Balance Sheet Location | September 30, 2026 | December 31, 2025 | |||||||||||||||||
| Assets: | ||||||||||||||||||||
| Accrued interest receivable on interest rate swap | Prepaid expenses and other current assets | $ | $ | |||||||||||||||||
| Accrued interest receivable on cross-currency rate swaps | Prepaid expenses and other currents assets | |||||||||||||||||||
| Interest rate swaps | Prepaid expenses and other currents assets | |||||||||||||||||||
| Total assets | $ | $ | ||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Interest rate swaps | Derivative liabilities, current | $ | $ | |||||||||||||||||
| Cross-currency rate swap | Derivative liabilities, current | |||||||||||||||||||
| Cross-currency rate swap | Other non-current liabilities | |||||||||||||||||||
| Total liabilities | $ | $ | ||||||||||||||||||
(1) Refer to Note 16, Fair Value Measurements, for additional information related to the estimated fair value.
Counterparty Credit Risk
Outstanding financial derivative instruments expose the Company to credit loss in the event of nonperformance by the counterparties to the derivative agreements. The Company's credit exposure related to these financial instruments is represented by the notional amount of the hedging instruments. The Company manages its exposure to counterparty credit risk through minimum credit standards, diversification of counterparties, and procedures to monitor concentrations of credit risk. The Company's derivative instruments are with financial institutions of investment grade or better. Counterparty credit risk will be monitored through periodic review of counterparty bank’s credit ratings and public financial filings. Based on these factors, the Company considers the risk of counterparty default to be minimal.
Hedges of Net Investments in Foreign Operations Strategy
The Company uses fixed-to-fixed cross-currency rate swaps (“CCRS”) to protect the net investment on pre-tax basis in the Company’s EUR-denominated operations against changes in spot exchange rates. For derivative financial instruments that are designated and qualify as hedges of net investments in foreign operations, the changes in the fair values of the derivative financial instruments are recognized in net investment hedges adjustments, a component of accumulated other comprehensive loss (“AOCL”), to offset the changes in the values of the net investments being hedged. Any ineffective portions of net investment hedges are reclassified from AOCL into earnings during the period of change.
39
The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges (in millions):
| Notional Amount | Gain (Loss) Recognized in AOCL | ||||||||||||||||||||||||||||||||||
| As of | Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||||||||||||||||||||||||||
| September 30, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||||||||
| Cross-currency rate swaps | € | € | $ | $ | $ | $ | ( | ||||||||||||||||||||||||||||
| Total | € | € | $ | $ | $ | $ | ( | ||||||||||||||||||||||||||||
In 2025, the Company amended one of the cross-currency rate swaps to extend the maturity to December 31, 2027. During nine months ended September 30, 2026, the Company amended another cross-currency rate swap to extend the maturity to December 29, 2028. As a part of each amendment, the relevant cross-currency rate swap was dedesignated from previous hedge accounting, and then redesignated as a net investment hedge, resulting in an immaterial off-market impact to the excluded interest component which will be recognized systematically into earnings over the life of the derivative.
The Company did not reclassify any gains or losses related to net investment hedges from AOCL into earnings during the nine months ended September 30, 2026 and September 30, 2025, respectively. In addition, the Company did not have any ineffectiveness related to net investment hedges during the nine months ended September 30, 2026 and September 30, 2025. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified as investing or financing activities in the unaudited Condensed Consolidated Statements of Cash Flows.
Cash Flow Hedging Strategy
The Company uses cash flow hedges to minimize the variability in cash flows of assets or liabilities or forecasted transactions caused by fluctuations in interest rates. The changes in the fair values of derivatives designated as cash flow hedges are recorded in AOCL and are reclassified into the line item in the unaudited Condensed Consolidated Statements of Operations in which the hedged items are recorded in the same period the hedged items affect earnings. The changes in the fair values of hedges that are determined to be ineffective are immediately reclassified from AOCL into earnings. The maximum length of time for which the Company hedges its exposure to the variability in future cash flows is three years .
40
18. Earnings Per Share
A reconciliation of the numerator and denominator used in the calculation of basic and diluted earnings per common share is as follows (in millions, except per share amounts):
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Net earnings attributable to Mirion Technologies, Inc. shareholders | $ | $ | $ | $ | |||||||||||||||||||
| Weighted average common shares outstanding — basic | |||||||||||||||||||||||
| Effect of potentially dilutive securities — stock-based awards | |||||||||||||||||||||||
| Effect of potentially dilutive securities — convertible debt | |||||||||||||||||||||||
| Weighted average common shares outstanding — diluted | |||||||||||||||||||||||
| Net earnings per common share attributable to Mirion Technologies, Inc. — basic | $ | $ | $ | $ | |||||||||||||||||||
| Net earnings per common share attributable to Mirion Technologies, Inc. — diluted | $ | $ | $ | $ | |||||||||||||||||||
Net earnings per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. Basic earnings per share is computed by dividing earnings available to common stockholders by the weighted average number of common shares outstanding, adjusted for the outstanding non-vested shares. Diluted earnings per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The weighted average number of potentially dilutive common shares related to employee stock-based awards excluded as anti-dilutive for the three and nine months ended September 30, 2026 were 3.951 million and 2.699 million, respectively.
The following classes of common stock were considered in the earnings per share calculation.
Class A Common Stock
Holders of shares of our Class A common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. The holders of our Class A common stock do not have cumulative voting rights in the election of directors. Holders of shares of our Class A common stock are entitled to receive dividends when and if declared by the Company's Board of Directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock. Upon our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our Class A common stock will be entitled to receive pro rata our remaining assets available for distribution. Class A common stock issued and outstanding is included in the Company’s basic earnings per share calculation.
Class B Common Stock
Holders of shares of our Class B common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. If at any time the ratio at which shares of IntermediateCo Class B common stock are redeemable or exchangeable for shares of our Class A common stock changes from one -for-one as the number of votes to which our Class B common stockholders are entitled will be
41
adjusted accordingly. The holders of our Class B common stock do not have cumulative voting rights in the election of directors. Except for transfers to us or to certain permitted transferees set forth in the IntermediateCo certificate of incorporation, paired interests may not be sold, transferred or otherwise disposed of.
Holders of shares of our Class B common stock are not entitled to economic interests in us or to receive dividends or to receive a distribution upon our liquidation or winding up, but are “paired interests” with shares of IntermediateCo Class B common stock. If IntermediateCo makes distributions to us other than solely with respect to our Class A common stock, the holders of paired interests will be entitled to receive distributions pro rata in accordance with the percentages of their respective shares of IntermediateCo Class B common stock.
Our Class B common stock has voting rights but no economic interest in the Company, and therefore shares are excluded from the calculation of basic and diluted earnings per share.
Stock-Based Awards
Each stock-based award represents the right to receive a Class A common stock upon vesting of the awards. Per ASC 260, “Earnings Per Share” (“EPS”), shares issuable for little or no cash consideration upon the satisfaction of certain conditions (i.e., contingently issuable shares) should be included in the computation of basic EPS as of the date that all necessary conditions have been satisfied. As such, any stock-based awards such as RSUs that vest will be included in the Company's basic earnings (loss) per share calculations as of the date when all necessary conditions are met. We determine the potential dilutive effect of outstanding stock-based awards on EPS using the treasury stock method.
Convertible Notes
During the year ended December 31, 2025, the Company issued $400.0 million aggregate principal amount of Convertible Notes due 2030 (the "2030 Notes") and an additional $375.0 million aggregate principal amount of Convertible Notes due 2031 (the "2031 Notes"). The initial conversion rate of the 2030 Notes and 2031 Notes is 43.2751 shares and 34.6951 shares, respectively, of Mirion’s Class A common stock per $1,000 principal amount of Notes. We determine the potential dilutive impact of the outstanding Notes on EPS using the if-converted method, assuming the conversion of the Notes as of the earliest period reported or at the date of issuance, if later. The effect of the related Capped Call transactions would be anti-dilutive and, as such, is excluded.
19. Restructuring and Impairment
The Company incurs costs associated with restructuring initiatives intended to improve operating performance, profitability, and working capital levels. Actions associated with these initiatives may include improving productivity, workforce reductions, and the consolidation of facilities.
As of September 30, 2026, the Company expects $1.9 million in additional charges from restructuring actions in the next 12 months.
42
The Company’s restructuring expenses are comprised of the following (in millions):
| Three Months Ended September 30, 2026 | |||||||||||||||||
| Cost of Revenues | Selling, general and administrative | Total | |||||||||||||||
| Severance and employee costs | $ | $ | $ | ||||||||||||||
| Total | $ | $ | $ | ||||||||||||||
| Three Months Ended September 30, 2025 | |||||||||||||||||
| Cost of Revenues | Selling, general and administrative | Total | |||||||||||||||
| Severance and employee costs | $ | $ | $ | ||||||||||||||
| Total | $ | $ | $ | ||||||||||||||
| Nine Months Ended September 30, 2026 | |||||||||||||||||
| Cost of Revenues | Selling, general and administrative | Total | |||||||||||||||
| Severance and employee costs | $ | $ | $ | ||||||||||||||
| Total | $ | $ | $ | ||||||||||||||
| Nine Months Ended September 30, 2025 | |||||||||||||||||
| Cost of Revenues | Selling, general and administrative | Total | |||||||||||||||
| Severance and employee costs | $ | $ | $ | ||||||||||||||
| Total | $ | $ | $ | ||||||||||||||
The following table summarizes restructuring expenses for each reportable segment (in millions):
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Restructuring expenses: | |||||||||||||||||||||||
| Nuclear & Safety | $ | $ | $ | $ | |||||||||||||||||||
| Medical | |||||||||||||||||||||||
| Corporate and other | |||||||||||||||||||||||
| Total | $ | $ | $ | $ | |||||||||||||||||||
The following table summarizes the changes in the Company’s accrued restructuring balance for severance and employee costs, which are included in accrued expenses and other current liabilities in the accompanying Condensed Consolidated Balance Sheets (in millions):
Balance at December 31, 2025 | $ | ||||
| Restructuring charges (excluding impairment) | |||||
| Payments | ( | ||||
| Adjustments | |||||
Balance at September 30, 2026 | $ | ||||
43
20. Noncontrolling Interests
The holders of IntermediateCo Class B common stock have the right to require IntermediateCo to redeem all or a portion of their IntermediateCo Class B common stock for, at the Company’s election, (1) newly issued shares of the Company’s Class A common stock on a one -for-one basis or (2) a cash payment equal to the product of the number of shares of IntermediateCo Class B common stock subject to redemption and the arithmetic average of the closing stock prices for a share of the Company’s Class A common stock for each of three (3 ) consecutive full trading days ending on and including the last full trading day immediately prior to the date of redemption (subject to customary adjustments, including for stock splits, stock dividends and reclassifications).
As of September 30, 2026, the Company recognized noncontrolling interests for the 5,759,555 shares, representing approximately 2.3 % of the non-voting Class B shares, of IntermediateCo that are not attributable to the Company. As of December 31, 2025, the Company recognized noncontrolling interests for the 5,869,555 shares, representing approximately 2.3 % of the non-voting Class B shares, of IntermediateCo that are not attributable to the Company.
21. Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss, net of tax, consist of the following (in millions):
| September 30, 2026 | December 31, 2025 | ||||||||||
| Cumulative foreign currency translation adjustment, net of tax | $ | ( | $ | ( | |||||||
| Unrealized gain on pension and postretirement benefit plans, net of tax | |||||||||||
| Unrealized loss on net investment hedges, net of tax | ( | ( | |||||||||
| Unrealized gain (loss) on cash flow hedges, net of tax | ( | ||||||||||
| Less: cumulative loss attributable to noncontrolling interests | ( | ( | |||||||||
| Accumulated other comprehensive loss | $ | ( | $ | ( | |||||||
22. Subsequent Events
The Company has performed an evaluation of subsequent events through the date of issuance of the financial statements, noting no items which require adjustment or disclosure.
44
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of Mirion’s financial condition and results of operations together with the unaudited Condensed Consolidated Financial Statements and related notes of Mirion Technologies, Inc. that are included elsewhere in this Quarterly Report on Form 10-Q as well as our audited consolidated financial statements and the notes related thereto for the year ended December 31, 2025 that are included in our Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section entitled “Risk Factors” included in this Quarterly Report on Form 10-Q as well as our Annual Report on Form 10-K. Unless the context otherwise requires, references in this section to “we,” “us,” “our,” “Mirion” and “the Company” refer to the business and operations of Mirion Technologies, Inc. and its consolidated subsidiaries. Unless the context otherwise requires or unless otherwise specified, all dollar amounts in this section are in millions.
Overview
We are a global provider of products, services, and software that allow our customers to safely leverage the power of ionizing radiation for the greater good of humanity through critical applications in the medical, nuclear and defense markets, as well as laboratories, scientific research, analysis, and exploration.
We provide dosimetry solutions for monitoring the total amount of radiation medical staff members are exposed to over time, radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy, and radionuclide therapy products for nuclear medicine applications such as shielding, product handling, and medical imaging furniture. We provide robust, field-ready personal radiation detection and identification equipment for defense applications and radiation detection and analysis tools for power plants, labs, and research applications. Nuclear power plant product offerings are used for the full nuclear power plant lifecycle including core detectors, essential measurement devices for new build, maintenance, decontamination and decommission, and equipment for monitoring and control during fuel dismantling and remote environmental monitoring.
We manage and report results of operations in two business segments: Nuclear & Safety and Medical.
•Our revenues were $277.8 million for the three months ended September 30, 2026 and $223.1 million for the three months ended September 30, 2025, of which 69.8% and 64.8% were generated in the Nuclear & Safety segment for the three months ended September 30, 2026 and 2025, respectively, and 30.2% and 35.2% were generated in the Medical segment for the three months ended September 30, 2026 and 2025, respectively.
•Our revenues were $802.2 million for the nine months ended September 30, 2026 and $648.0 million for the nine months ended September 30, 2025, of which 70.5% and 64.8% were generated in the Nuclear & Safety segment for the nine months ended September 30, 2026 and 2025, respectively, and 29.5% and 35.2% were generated in the Medical segment for the nine months ended September 30, 2026 and 2025, respectively.
•Backlog (representing committed but undelivered contracts and purchase orders) was $1,248.2 million and $1,104.3 million as of September 30, 2026, and December 31, 2025, respectively.
Our Business Segments
We manage and report our business in two business segments: Nuclear & Safety and Medical.
Nuclear & Safety includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For Nuclear Power Plants (“NPPs”), we sell products and services for use at any stage of their life (construction, operation, decommissioning and dismantling), with NPPs representing the majority of our sales into the nuclear end market.
Medical includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance ("RT QA"), which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The advancing field of Nuclear Medicine is also served by this segment including products for radiation measurement, product handling, and medical imaging, inclusive of software across the radiopharmaceutical lifecycle. Dosimetry solutions monitor the total amount of radiation medical staff members are exposed to over time.
45
Key Factors Affecting Our Performance
We believe that our business and results of operations and financial condition may be impacted in the future by various trends, conditions and risks. The Board has overall oversight responsibility for our risk management. During 2024, the Company initiated a formal Enterprise Risk Management program (“ERM”) where management and Internal Audit provide updates to the Board. These discussions include identification and scoring of key business risks and management's plans and progress to address identified focus areas.
The following key factors have affected our performance, and we anticipate they will continue to affect our future results:
•Nuclear end market trends—Growth and operating results in our Nuclear & Safety segment are impacted by:
•Our products are installed at the vast majority of addressable active nuclear power reactors globally, creating full lifecycle sales opportunities. This installed base drives recurring revenue through replacement and service cycles associated with our offerings and the typical 40 to 100 year operating life cycle of a NPP;
•The emerging megatrends surrounding the power demands of data centers, cloud computing, and artificial intelligence that can be served by Nuclear;
•Products supporting the development of new technologies within the Nuclear end market, including Small Modular Reactors (“SMRs”);
•Increased government and industry acceptance of Nuclear as (a) a clean energy source, and (b) a viable option for domestic energy production in efforts to rely less on international imports; and
•Decisions by governments to build new power plants or decommission existing plants can positively and negatively impact our customer base.
•Medical end market trends—Growth and operating results in our Medical segment are impacted by:
•Medical RT QA growth driven by growing and aging population demographics, low penetration of RT QA technology in emerging markets, and increased adoption of advanced software and hardware solutions for improved outcomes and administrative and labor efficiencies;
•Changes to global regulatory standards, including new or expanded standards;
•Increased focus on healthcare safety;
•Medical/lab dosimetry growth supported by growing and aging demographics, increased number of healthcare professionals, and penetration of radiation therapy/diagnostics;
•Changes to healthcare reimbursement; and
•Potential budget constraints in hospitals and other healthcare providers.
•We believe the focus of government policy in China is on expanding access to healthcare. In addition, our investments to address clinical needs, localization, and its growing population should benefit our business in China in the long term. However, we continue to monitor developments in the China market, including increased competition from local companies and the prevalence of volume based procurement policies, both of which have and may continue to impact our orders and revenues.
•Nuclear new build projects, including SMRs —A portion of our remaining performance obligations is driven by contracts associated with the construction of new nuclear power plants. These contracts can be long-term in nature and provide us with a strong pipeline for the recognition of future revenues in our Nuclear & Safety segment. We perform our services and provide our products at a fixed price for certain contracts. Fixed-price contracts carry inherent risks, including risks of losses from underestimating costs, operational difficulties and other changes that may occur over the contract period. SMRs have an additional risk of underestimation of costs given the technology is new and still under development for commercial applications. If our cost estimates for a contract are inaccurate or if we do not execute the contract within our cost estimates, we may incur losses or the contract may not be as profitable as we expected. In addition, even though some of our longer-term contracts contain price escalation provisions, such provisions may not fully provide for cost increases, whether from inflation, the cost of goods and services to be delivered under such contracts or otherwise.
•Geopolitical and trade conditions—Geopolitical and trade conditions, including related to matters affecting Russia, the relationship between the United States and China, and conflict in the Middle East (including the U.S.-Israel-Iran conflict), have impacted and may continue to impact us, through increased inflation, limited availability of certain commodities, supply chain disruption, disruptions to our global technology infrastructure, including cyberattacks, increased terrorist activities, volatility or disruption in the capital markets, and delays or cancellations of customer projects.
•Inflation and interest rates—We continue to actively monitor, evaluate and respond to developments relating to operational challenges in the current inflationary environment. Global supply chain disruptions and the higher
46
inflationary environment remain unpredictable and our past results may not be indicative of future performance. In addition, the increase in interest rates has in turn led to increases in the interest rates applicable to our indebtedness and increased our debt service costs.
•Sanctions—There are, at any given time, a multitude of ongoing or threatened armed conflicts around the world. As one example, sanctions by the United States, the European Union, and other countries against Russian entities or individuals related to the Russia-Ukraine conflict, along with any Russian retaliatory measures could increase our costs, adversely affect our operations, or impact our ability to meet existing contractual obligations.
•Strategic transactions—A large driver of our historical growth has been the acquisition and integration of related businesses. Our ability to integrate, restructure, and leverage synergies of these businesses will impact our operating results over time. From time to time we also divest businesses, which could also impact our operating results.
•Government budgets—While we believe that we are poised for growth from governmental customers in both of our segments, our revenues and cash flows from government customers are influenced, particularly in the short-term, by budgetary cycles. This impact can be either positive or negative, primarily related to revenues in our labs and research, defense, and medical segment end markets.
•Research and development—A portion of our operating expenses is associated with research and development activities associated with the design of new products. Given the specific design and application of these products, there is some risk that these costs will not result in successful products in the market. Further, the timing of these products can move and be challenging to predict.
•Financial risks—Our business and financial statements can be adversely affected by foreign currency exchange rates, changes in interest rates, recognition of impairment charges for our goodwill or other intangible assets and fluctuations in the cost and availability of commodities. No triggering events for interim goodwill impairment testing occurred in the third quarter of 2026. However, the Company will continue to monitor macroeconomic conditions for future changes in assumptions or deterioration in market conditions, including impacts from rising long-term interest rates and geopolitical risks impacting global trade conditions, which could result in an impairment in one or more of the Company's reporting units. Our required annual goodwill impairment assessment for all reporting units will be performed during the fourth quarter of 2026.
•Global risk, including tariffs—Our business depends in part on operations and sales outside the United States. Risks related to those international operations and sales include new foreign investment laws, new export/import regulations, and additional trade restrictions (such as tariffs, sanctions, and embargoes). New laws that favor local competitors could prevent our ability to compete outside the United States. Additional potential issues are associated with the impact of these same risks on our suppliers and customers. If our customers or suppliers are impacted by these risk factors, we may see the reduction or cancellation of customer orders, or interruptions in the supply of raw materials and components.
•Tax risks—Our business and financial statements can be adversely affected by changes in tax rates or exposure to tax liabilities/assessments:
•Our effective tax rate could be impacted by changes in tax laws;
•Audits or assessments by tax authorities could result in additional tax payments for prior periods;
•Foreign remittance taxes have not been provided on undistributed earnings of certain of our non-U.S. subsidiaries to the extent such earnings are considered to be indefinitely reinvested in operations. Changes in our intentions regarding reinvestment of such earnings could impact our income tax provision, cash taxes paid and effective tax rate; and
•Many countries have incorporated Pillar Two global minimum tax rules into their domestic laws. Pillar Two legislation was effective for the Company for the year ended December 31, 2025. While we continue to expect the impact to be immaterial, Pillar Two could impact our cash taxes paid and effective tax rate.
Recent Developments
Paragon Acquisition
On December 1, 2025, Mirion acquired 100% of the outstanding membership interest of WCI-Gigawatt Intermediate Holdco, LLC, the indirect parent of Paragon Energy Solutions, LLC (“Paragon”) for $588.6 million of gross purchase consideration ($581.5 million, net of cash and net working capital adjustment). As part of the Nuclear & Safety segment, Paragon is a leading provider of highly engineered solutions for large-scale nuclear power plants and small modular reactors (SMRs) in the United States. Mirion management believes that Paragon will provide Mirion's nuclear power customers with a more comprehensive suite of product offerings and services to meet their growing needs. Additionally, the addition of Paragon significantly enhances our presence in the U.S. nuclear power market and the developing SMR
47
commercial entrants.
Russia and China
The United States, the European Union, the United Kingdom and other governments have implemented major trade and financial sanctions against Russia, China, and related parties. Additionally, China continues to expand localization requirements that could require us to localize manufacturing or source local components, or to otherwise modify our business operations. We do business with Russian and Chinese customers both within and outside of Russia and China, as well as with customers who have contracts with Russian and Chinese counterparties. The impact on the Company is predominantly in our Nuclear & Safety segment. As of September 30, 2026, the Company has approximately $17.7 million in net contract assets for Russian and Chinese customers and channel partners. The Company maintains $10.7 million in advance payment guarantees in support of these projects. The remaining performance obligations in our backlog for Russian-related projects and Chinese parts and services contracts were approximately $163.4 million at September 30, 2026.
While we have not experienced significant impacts to our business results from these sanctions and localization requirements, the Company will continue to monitor the social, political, regulatory and economic environment in Russia and China, and will consider actions as appropriate.
Non-GAAP Financial Measures
We report our financial results in accordance with generally accepted accounting principles in the United States. (“GAAP”). However, management believes certain non-GAAP financial measures provide investors and other users with additional meaningful information that should be considered when assessing our ongoing performance. Management also uses these non-GAAP financial measures in making financial, operating, and planning decisions, and in evaluating our performance. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, our GAAP results. The non-GAAP financial measures we present may differ from similarly captioned measures presented by other companies. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
In particular, we use the non-GAAP financial measures “EBITA,” “EBITDA,” and “Adjusted EBITDA.” “Adjusted EBITDA” is used in the calculation of the First Lien Net Leverage Ratio in the 2021 Credit Agreement described in Note 8, Borrowings, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
48
The following tables present a reconciliation of certain non-GAAP financial measures for the three and nine months ended September 30, 2026 and for the three and nine months ended September 30, 2025.
| (In millions) | Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | |||||||||
| Net income | $ | 7.8 | $ | 3.1 | |||||||
| Interest expense, net | 5.7 | 6.7 | |||||||||
| Income tax expense (benefit) | 3.1 | (1.9) | |||||||||
| Amortization | 29.4 | 25.7 | |||||||||
| EBITA | $ | 46.0 | $ | 33.6 | |||||||
| Depreciation | 8.8 | 9.1 | |||||||||
| EBITDA | $ | 54.8 | $ | 42.7 | |||||||
| Stock-based compensation expense | 7.1 | 4.4 | |||||||||
| Foreign currency loss (gain), net | 0.1 | (0.6) | |||||||||
| Cost of revenues impact from inventory valuation purchase accounting | (0.3) | — | |||||||||
Non-operating expenses(1)(2) | 3.1 | 5.9 | |||||||||
| Adjusted EBITDA | $ | 64.8 | $ | 52.4 | |||||||
(1)Pre-tax non-operating expenses of $3.1 million for the three months ended September 30, 2026 include $2.2 million of mergers and acquisition expenses, primarily consistent of nonrecurring third-party consulting and professional fees, and $0.8 million of restructuring and other related costs.
(2)Pre-tax non-operating expenses of $5.9 million for the three months ended September 30, 2025 include $3.9 million of mergers and acquisition expenses; $1.0 million of restructuring and other related costs; $0.6 million of one-time consulting fees related to IT services sourcing excellence; and $0.3 million of consulting costs related to Nuclear & Safety segment enterprise resource planning software upgrades.
| (In millions) | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||||
| Net income | $ | 12.5 | $ | 12.0 | |||||||
| Interest expense, net | 16.5 | 27.1 | |||||||||
| Income tax expense (benefit) | 4.5 | (2.4) | |||||||||
| Amortization | 90.4 | 76.3 | |||||||||
| EBITA | $ | 123.9 | $ | 113.0 | |||||||
| Depreciation | 27.4 | 26.1 | |||||||||
| EBITDA | $ | 151.3 | $ | 139.1 | |||||||
| Stock-based compensation expense | 18.3 | 11.2 | |||||||||
| Foreign currency loss (gain), net | 4.8 | (16.9) | |||||||||
| Loss on debt extinguishment and other related costs | — | 6.3 | |||||||||
| Cost of revenues impact from inventory valuation purchase accounting | 1.3 | — | |||||||||
Non-operating expenses(1)(2) | 8.7 | 10.6 | |||||||||
| Adjusted EBITDA | $ | 184.4 | $ | 150.3 | |||||||
(1)Pre-tax non-operating expenses of $8.7 million for the nine months ended September 30, 2026 include $7.0 million of mergers and acquisitions expenses, primarily consisting of nonrecurring third-party consulting and professional fees, and $1.4 million of restructuring and other related costs.
(2)Pre-tax non-operating expenses of $10.6 million for the nine months ended September 30, 2025 include $4.2 million of mergers and acquisition expenses; $2.9 million of restructuring and other related costs; $1.3 million of one-time consulting fees related to IT services sourcing excellence; $1.1 million of consulting costs related to Nuclear & Safety segment enterprise resource planning software upgrades; and $1.0 million of asset impairment charges of our equity investment (100% impairment).
49
The following tables present a reconciliation of GAAP income from operations to non-GAAP Adjusted EBITDA by segment for the three and nine months ended September 30, 2026 and the three and nine months ended September 30, 2025.
| Three Months Ended September 30, 2026 | |||||||||||||||||||||||
| (In millions) | Nuclear & Safety | Medical | Corporate & Other | Consolidated | |||||||||||||||||||
| Income from operations | $ | 25.9 | $ | 15.6 | $ | (24.3) | $ | 17.2 | |||||||||||||||
| Amortization | 18.9 | 10.5 | — | 29.4 | |||||||||||||||||||
| Depreciation | 3.7 | 4.9 | 0.2 | 8.8 | |||||||||||||||||||
| Stock-based compensation | 0.8 | 0.5 | 5.8 | 7.1 | |||||||||||||||||||
| Cost of revenues impact from inventory valuation purchase accounting | (0.3) | — | — | (0.3) | |||||||||||||||||||
| Non-operating expenses | 0.9 | 0.4 | 1.8 | 3.1 | |||||||||||||||||||
| Other expense / (income) | (0.1) | (0.2) | (0.2) | (0.5) | |||||||||||||||||||
| Adjusted EBITDA | $ | 49.8 | $ | 31.7 | $ | (16.7) | $ | 64.8 | |||||||||||||||
| Three Months Ended September 30, 2025 | |||||||||||||||||||||||
| (In millions) | Nuclear & Safety | Medical | Corporate & Other | Consolidated | |||||||||||||||||||
| Income from operations | $ | 21.3 | $ | 10.7 | $ | (24.6) | $ | 7.4 | |||||||||||||||
| Amortization | 14.3 | 11.4 | — | 25.7 | |||||||||||||||||||
| Depreciation | 3.6 | 5.3 | 0.2 | 9.1 | |||||||||||||||||||
| Stock-based compensation | 0.7 | 0.5 | 3.2 | 4.4 | |||||||||||||||||||
| Non-operating expenses | 0.7 | 0.6 | 4.1 | 5.4 | |||||||||||||||||||
| Other expense / (income) | — | (0.3) | 0.7 | 0.4 | |||||||||||||||||||
| Adjusted EBITDA | $ | 40.6 | $ | 28.2 | $ | (16.4) | $ | 52.4 | |||||||||||||||
| Nine Months Ended September 30, 2026 | |||||||||||||||||||||||
| (In millions) | Nuclear & Safety | Medical | Corporate & Other | Consolidated | |||||||||||||||||||
| Income from operations | $ | 72.8 | $ | 38.2 | $ | (72.2) | $ | 38.8 | |||||||||||||||
| Amortization | 57.7 | 32.7 | — | 90.4 | |||||||||||||||||||
| Depreciation | 12.1 | 14.5 | 0.8 | 27.4 | |||||||||||||||||||
| Stock-based compensation | 2.5 | 1.6 | 14.2 | 18.3 | |||||||||||||||||||
| Cost of revenues impact from inventory valuation purchase accounting | 1.3 | — | — | 1.3 | |||||||||||||||||||
| Non-operating expenses | 1.2 | 0.7 | 6.8 | 8.7 | |||||||||||||||||||
| Other expense / (income) | — | (0.3) | (0.2) | (0.5) | |||||||||||||||||||
| Adjusted EBITDA | $ | 147.6 | $ | 87.4 | $ | (50.6) | $ | 184.4 | |||||||||||||||
| Nine Months Ended September 30, 2025 | |||||||||||||||||||||||
| (In millions) | Nuclear & Safety | Medical | Corporate & Other | Consolidated | |||||||||||||||||||
| Income from operations | $ | 62.0 | $ | 28.3 | $ | (64.3) | $ | 26.0 | |||||||||||||||
| Amortization | 41.7 | 34.6 | — | 76.3 | |||||||||||||||||||
| Depreciation | 10.5 | 14.8 | 0.8 | 26.1 | |||||||||||||||||||
| Stock-based compensation | 1.5 | 1.3 | 8.4 | 11.2 | |||||||||||||||||||
| Non-operating expenses | 1.7 | 3.2 | 5.7 | 10.6 | |||||||||||||||||||
| Other expense / (income) | 0.3 | (0.7) | 0.5 | 0.1 | |||||||||||||||||||
| Adjusted EBITDA | $ | 117.7 | $ | 81.5 | $ | (48.9) | $ | 150.3 | |||||||||||||||
50
Basis of Presentation
Financial information presented was derived from our historical consolidated financial statements and accounting records, and they reflect the historical financial position, results of operations and cash flows of the business in conformity with U.S. GAAP for financial statements and pursuant to the accounting and disclosure rules and regulations of the SEC. The consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned or controlled subsidiaries. For consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to noncontrolling interests is reported as “Income (loss) attributable to noncontrolling interests” in the unaudited Condensed Consolidated Statements of Operations. All intercompany accounts and transactions have been eliminated in consolidation.
51
Results of Operations
For the Three Months Ended September 30, 2026 and the Three Months Ended September 30, 2025
The following table summarizes our results of operations for the periods presented below (in millions):
| Unaudited | |||||||||||
| Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | ||||||||||
| Revenues | $ | 277.8 | $ | 223.1 | |||||||
| Cost of revenues | 146.3 | 118.6 | |||||||||
| Gross profit | 131.5 | 104.5 | |||||||||
| Selling, general and administrative expenses | 104.0 | 87.0 | |||||||||
| Research and development | 10.3 | 10.1 | |||||||||
| Income from operations | 17.2 | 7.4 | |||||||||
| Interest expense, net | 5.7 | 6.7 | |||||||||
| Foreign currency loss (gain), net | 0.1 | (0.6) | |||||||||
| Other (income) expense, net | 0.5 | 0.1 | |||||||||
| Income before income taxes | 10.9 | 1.2 | |||||||||
| Income tax expense (benefit) | 3.1 | (1.9) | |||||||||
| Net income | 7.8 | 3.1 | |||||||||
| Income attributable to noncontrolling interests | 0.4 | 0.2 | |||||||||
| Net income attributable to Mirion Technologies, Inc. | $ | 7.4 | $ | 2.9 | |||||||
Overview
Revenues were $277.8 million for the three months ended September 30, 2026 and $223.1 million for the three months ended September 30, 2025. Our Nuclear & Safety segment contributed $194.0 million and $144.6 million of revenues for the three months ended September 30, 2026 and 2025, respectively. Our Medical segment contributed $83.8 million and $78.5 million of revenues for the three months ended September 30, 2026 and 2025, respectively. Gross profit was $131.5 million and $104.5 million for the three months ended September 30, 2026 and 2025, respectively, resulting in a $27.0 million increase from the three months ended September 30, 2025.
Net income was $7.8 million for the three months ended September 30, 2026 and net income was $3.1 million for the three months ended September 30, 2025. Our Nuclear & Safety segment contributed $25.9 million and $21.3 million of income from operations for the three months ended September 30, 2026 and 2025, respectively. Our Medical segment contributed $15.6 million and $10.7 million of income from operations for the three months ended September 30, 2026 and 2025, respectively. The overall increase in net income is primarily driven by increased revenues in both segments, primarily driven by acquisitions, improved gross profit margins, and decreased interest expense. Partially offsetting these items was an increase in income tax expense, increased amortization of intangible assets associated with recent acquisitions, and increased employee compensation costs.
Revenues
Revenues were $277.8 million for the three months ended September 30, 2026 and $223.1 million for the three months ended September 30, 2025. Revenues increased $54.7 million from the three months ended September 30, 2025.
Nuclear & Safety segment revenues increased for the three months ended September 30, 2026 compared with the three months ended September 30, 2025 primarily due to organic volume growth, price increases and recent acquisitions, partially offset by negative foreign exchange fluctuations.
Medical segment revenues increased for the three months ended September 30, 2026 compared with the three months ended September 30, 2025 due to organic volume growth, primarily within the cameras product line, and price increases.
52
Cost of revenues
Cost of revenues was $146.3 million for the three months ended September 30, 2026 and $118.6 million for the three months ended September 30, 2025, an increase of $27.7 million period over period.
Cost of revenues related to the Nuclear & Safety segment increased $24.9 million period over period. The increase was primarily driven by organic volume growth of $2.7 million, inflation of $1.7 million, and costs associated with recent acquisitions of $20.5 million. These changes were also impacted by positive margin mix impact within our France and Europe locations, offset by negative margin mix within our legacy North America business.
Cost of revenues related to the Medical segment increased $2.8 million period over period due to increased organic sales volume, inflation, and a specific product one-time quality cost impact within our Nuclear Medicine division.
Selling, general and administrative expenses
Selling, general and administrative (“SG&A”) expenses were $104.0 million for the three months ended September 30, 2026 and $87.0 million for the three months ended September 30, 2025, resulting in an increase of $17.0 million period over period.
Our Nuclear & Safety segment incurred higher SG&A expenses of $18.6 million for the three months ended September 30, 2026 compared with the three months ended September 30, 2025. The increase was driven by increased employee compensation costs related to newly acquired entities, amortization expense from newly acquired intangible assets, increased incentive compensation in the current year, and increased facility costs.
Our Medical segment incurred lower SG&A expenses of $2.4 million for the three months ended September 30, 2026 compared with the three months ended September 30, 2025. The decrease was driven by decreased incentive compensation and lower amortization expense for intangible assets.
Corporate SG&A expenses were $20.5 million for the three months ended September 30, 2026 and $19.7 million for the three months ended September 30, 2025. The increase of $0.8 million was primarily driven by increased compensation costs, primarily additional stock compensation expenses largely related to performance stock options ("PSOs") granted during the current year, partially offset by a decrease in mergers and acquisition expenses as compared to the prior period.
Research and development
Research and development (“R&D”) expenses were $10.3 million for the three months ended September 30, 2026 and $10.1 million for the three months ended September 30, 2025, resulting in an increase of $0.2 million period over period.
Income from operations
Income from operations was $17.2 million for the three months ended September 30, 2026 compared with $7.4 million for the three months ended September 30, 2025. On a segment basis, income from operations in the Nuclear & Safety segment for the three months ended September 30, 2026 and three months ended September 30, 2025 was $25.9 million and $21.3 million, respectively, representing an increase of $4.6 million period over period. Income from operations in the Medical segment for the three months ended September 30, 2026 and 2025 was $15.6 million and $10.7 million, respectively, representing an increase of $4.9 million period over period. Corporate loss from operations was $24.3 million and $24.6 million for the three months ended September 30, 2026 and 2025, respectively, representing a decrease in loss of $0.3 million period over period. See “Business segments” and “Corporate and other” below for further details.
Interest expense, net
Interest expense, net, was $5.7 million for the three months ended September 30, 2026 and $6.7 million for the three months ended September 30, 2025. The $1.0 million decrease in interest expense, net, was due to additional interest earned on cash deposits in the current period.
Foreign currency loss (gain), net
We recorded a $0.1 million net loss for the three months ended September 30, 2026 and a $0.6 million net gain for the three months ended September 30, 2025 from foreign currency exchange. The change in foreign currency loss (gain), net is
53
due primarily to fluctuations in European local currencies in relation to the U.S. dollar and the related impact on our intercompany loans.
Income taxes
The effective income tax rate was 28.4% and (158.3)% for the three months ended September 30, 2026 and 2025, respectively. The difference in effective tax rate between the periods was primarily attributable to mix of earnings.
The effective income tax rate differs from the U.S. statutory rate of 21% due primarily to U.S. federal income tax permanent differences and the impact of valuation allowances.
Business segments
The following provides detail for business segment results for the three months ended September 30, 2026 and 2025. Segment income from operations includes revenues of the segment less expenses that are directly related to those revenues but excludes certain charges to cost of revenues and SG&A expenses predominantly related to corporate costs, which are included in Corporate and Other in the table below. Interest expense, foreign currency loss (gain), net, and other expense (income), net, are not allocated to segments.
For reconciliations of segment revenues and operating (loss) income to our consolidated results, see Note 15, Segment Information, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
Nuclear & Safety
| Unaudited | |||||||||||
| (In millions) | Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | |||||||||
| Revenues | $ | 194.0 | $ | 144.6 | |||||||
| Income from operations | $ | 25.9 | $ | 21.3 | |||||||
| Income from operations as a % of revenues | 13.4 | % | 14.7 | % | |||||||
Nuclear & Safety segment revenues increased for the three months ended September 30, 2026 compared with the three months ended September 30, 2025 primarily due to $6.9 million of organic volume growth, $2.3 million of price increases, partially offset by negative foreign exchange fluctuations of $1.2 million. Additional drivers include $41.4 million of revenue associated with recent acquisitions.
Income from operations was $25.9 million and $21.3 million for the three months ended September 30, 2026 and 2025, respectively. Income from operations increased $4.6 million period over period driven primarily by the changes in revenues described above. These changes were partially offset by increased employee compensation costs of $7.9 million, primarily associated with recent acquisitions, purchase accounting intangibles amortization of $7.5 million, and increased incentive compensation of $2.6 million, partially offset by a reduction in intangibles amortization associated with our legacy businesses of $1.4 million.
Medical
| Unaudited | |||||||||||
| (In millions) | Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | |||||||||
| Revenues | $ | 83.8 | $ | 78.5 | |||||||
| Income from operations | $ | 15.6 | $ | 10.7 | |||||||
| Income from operations as a % of revenues | 18.6 | % | 13.6 | % | |||||||
54
Medical segment revenues increased for the three months ended September 30, 2026 compared with the three months ended September 30, 2025 due to $3.5 million in organic volume growth, primarily within the cameras product line, and $1.8 million of price increases.
Income from operations was $15.6 million and $10.7 million for the three months ended September 30, 2026 and 2025, respectively, representing a $4.9 million increase in income from operations period over period. The increase in income from operations period over period was largely due to increased revenues as described above, a reduction in amortization expense of $0.8 million and decreased incentive compensation costs of $0.8 million. This was partially offset by $1.0 million in a specific product one-time quality cost impact within our Nuclear Medicine division.
Corporate and other
Corporate and other costs include costs associated with our corporate headquarters located in Georgia, as well as centralized global functions including Executive, Finance, Legal and Compliance, Human Resources, Technology, Strategy, and Marketing and other costs related to company-wide initiatives (e.g., business combination transaction expenses, merger and acquisition activities, restructuring and other initiatives).
Corporate and other costs were $24.3 million for the three months ended September 30, 2026 and $24.6 million for the three months ended September 30, 2025, which represents a decrease of $0.3 million period over period.
For reconciliations of segment operating income and corporate and other costs to our consolidated results, see Note 15, Segment Information, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
For the Nine Months Ended September 30, 2026 and the Nine Months Ended September 30, 2025
The following table summarizes our results of operations for the periods presented below (in millions):
| Unaudited | |||||||||||
| Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | ||||||||||
| Revenues | $ | 802.2 | $ | 648.0 | |||||||
| Cost of revenues | 418.5 | 344.9 | |||||||||
| Gross profit | 383.7 | 303.1 | |||||||||
| Selling, general and administrative expenses | 314.9 | 248.3 | |||||||||
| Research and development | 30.0 | 28.8 | |||||||||
| Income from operations | 38.8 | 26.0 | |||||||||
| Interest expense, net | 16.5 | 27.1 | |||||||||
| Loss on debt extinguishment | — | 5.8 | |||||||||
| Foreign currency loss (gain), net | 4.8 | (16.9) | |||||||||
| Other expense, net | 0.5 | 0.4 | |||||||||
| Income before income taxes | 17.0 | 9.6 | |||||||||
| Income tax expense (benefit) | 4.5 | (2.4) | |||||||||
| Net income | 12.5 | 12.0 | |||||||||
| Income attributable to noncontrolling interests | 0.8 | 0.5 | |||||||||
| Net income attributable to Mirion Technologies, Inc. | $ | 11.7 | $ | 11.5 | |||||||
Overview
Revenues were $802.2 million for the nine months ended September 30, 2026 and $648.0 million for the nine months ended September 30, 2025. Our Nuclear & Safety segment contributed $565.7 million and $419.7 million of revenues for the nine months ended September 30, 2026 and 2025, respectively. Our Medical segment contributed $236.5 million and $228.3 million of revenues for the nine months ended September 30, 2026 and 2025, respectively. Gross profit was $383.7 million and $303.1 million for the nine months ended September 30, 2026 and 2025, respectively, resulting in a $80.6 million increase from the nine months ended September 30, 2025.
55
Net income was $12.5 million for the nine months ended September 30, 2026 and $12.0 million for the nine months ended September 30, 2025. Our Nuclear & Safety segment contributed $72.8 million and $62.0 million of income from operations for the nine months ended September 30, 2026 and 2025, respectively. Our Medical segment contributed $38.2 million and $28.3 million of income from operations for the nine months ended September 30, 2026 and 2025, respectively. The overall increase in net income is primarily driven by increased revenues in both segments, primarily driven by acquisitions, improved gross margins, decreased interest expense, and a nonrecurring $5.8 million loss on debt extinguishment in the prior period. Partially offsetting these items were a $4.8 million unrealized foreign currency loss in the current period as opposed to a $16.9 million gain in the prior period as a result of fluctuations in the exchange rate between the US Dollar and the Euro, increased employee compensation costs, increased amortization of intangible assets associated with recent acquisitions, and an increase in income tax expense.
Revenues
Revenues were $802.2 million for the nine months ended September 30, 2026 and $648.0 million for the nine months ended September 30, 2025. Revenues increased $154.2 million from the nine months ended September 30, 2025.
Nuclear & Safety segment revenues increased for the nine months ended September 30, 2026 compared with the nine months ended September 30, 2025 primarily due to organic volume growth, with increases across all end markets with the exception of labs and research, positive foreign exchange fluctuations, price increases, and recent acquisitions.
Medical segment revenues increased for the nine months ended September 30, 2026 compared with the nine months ended September 30, 2025 primarily due to price increases, organic volume growth within the cameras product line, and positive foreign exchange fluctuations. These changes were partially offset by a decline in volume growth within other product lines, specifically within Asia-Pacific countries due to the introduced tariff regime in prior years paired with a decline in dosimetry product sales.
Cost of revenues
Cost of revenues was $418.5 million for the nine months ended September 30, 2026 and $344.9 million for the nine months ended September 30, 2025, an increase of $73.6 million period over period.
Cost of revenues related to the Nuclear & Safety segment increased $74.3 million period over period. The increase was primarily driven by inflation of $5.3 million, organic volume growth of $4.0 million, and foreign exchange impacts of $3.2 million. These were partially offset by positive margin impacts of $1.5 million, primarily within our France and Europe locations and partially offset by negative margin impacts within our legacy North America business. Also impacting the increase were costs associated with the recent acquisitions of $63.3 million.
Cost of revenues related to the Medical segment increased $1.2 million period over period primarily due to inflation.
Selling, general and administrative expenses
Selling, general and administrative (“SG&A”) expenses were $314.9 million for the nine months ended September 30, 2026 and $248.3 million for the nine months ended September 30, 2025, resulting in an increase of $66.6 million period over period.
Our Nuclear & Safety segment incurred higher SG&A expenses of $60.0 million for the nine months ended September 30, 2026 compared with the nine months ended September 30, 2025. The increase was driven by increased employee compensation costs, primarily related to stock compensation awarded to employees at recently acquired entities, amortization expense from newly acquired intangible assets, and increased facility costs.
Our Medical segment incurred lower SG&A expenses of $3.7 million for the nine months ended September 30, 2026 compared with the nine months ended September 30, 2025. The decrease was primarily due to lower amortization expense and a decrease in bad debt expense from the prior year. Partially offsetting these savings were increased employee compensation costs.
Corporate SG&A expenses were $65.0 million for the nine months ended September 30, 2026 and $54.7 million for the nine months ended September 30, 2025. The increase of $10.3 million was primarily driven by increased stock compensation costs, including additional expense related to PSOs granted during the current year, costs associated with the establishment of a new artificial intelligence function, and increased current period mergers and acquisition related expenses.
Corporate SG&A expenses were $65.0 million for the nine months ended September 30, 2026 and $54.7 million for the nine months ended September 30, 2025. The increase of $10.3 million was primarily driven by increased stock compensation costs, including additional expense related to PSOs granted during the current year, costs associated with the establishment of a new artificial intelligence function, and increased current period mergers and acquisition related expenses.
56
Research and development
Research and development (“R&D”) expenses were $30.0 million for the nine months ended September 30, 2026 and $28.8 million for the nine months ended September 30, 2025, resulting in an increase of $1.2 million period over period. The increase was primarily driven by $1.0 million in additional expenses from recently acquired entities.
Income from operations
Income from operations was $38.8 million for the nine months ended September 30, 2026 compared with $26.0 million for the nine months ended September 30, 2025. On a segment basis, income from operations in the Nuclear & Safety segment for the nine months ended September 30, 2026 and nine months ended September 30, 2025 was $72.8 million and $62.0 million, respectively, representing an increase of $10.8 million period over period. Income from operations in the Medical segment for the nine months ended September 30, 2026 and 2025 was $38.2 million and $28.3 million, respectively, representing an increase of $9.9 million period over period. Corporate loss from operations was $72.2 million and $64.3 million for the nine months ended September 30, 2026 and 2025, respectively, representing an increased loss of $7.9 million period over period. See “Business segments” and “Corporate and other” below for further details.
Interest expense, net
Interest expense, net, was $16.5 million for the nine months ended September 30, 2026 and $27.1 million for the nine months ended September 30, 2025. The $10.6 million decrease in interest expense, net was due to decreased interest rates from the prior period, full year impacts of the $244.6 million decrease in the term loan balance as a result of the debt refinancing during the nine months ended September 30, 2025, the 0.25% interest rate negotiated on the $400.0 million Convertible Debt offering completed during the nine months ended September 30 2025, and additional interest earned on cash deposits in the current period. For more information, see Note 8, Borrowings, Note 9, Convertible Debt, and Note 17, Derivatives and Hedging, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
Loss on debt extinguishment
Loss on debt extinguishment was $5.8 million for the nine months ended September 30, 2025, related to the refinancing of the term loan completed on June 5, 2025.
Foreign currency (gain) loss, net
We recorded a $4.8 million net loss for the nine months ended September 30, 2026 and a $16.9 million net gain for the nine months ended September 30, 2025 from foreign currency exchange. The change in foreign currency loss (gain), net is due primarily to fluctuations in European local currencies in relation to the U.S. dollar and the related impact on our intercompany loans.
Income taxes
The effective income tax rate was 26.5% and (25.0)% for the nine months ended September 30, 2026 and 2025, respectively. The difference in effective tax rate between the periods was primarily attributable to mix of earnings.
The effective income tax rate differs from the U.S. statutory rate of 21% due primarily to U.S. federal income tax permanent differences and the impact of valuation allowances.
Business segments
The following provides detail for business segment results for the nine months ended September 30, 2026 and 2025. Segment income from operations includes revenues of the segment less expenses that are directly related to those revenues but excludes certain charges to cost of revenues and SG&A expenses predominantly related to corporate costs, which are included in Corporate and Other in the table below. Interest expense, foreign currency loss (gain), net, loss on debt extinguishment, and other expense (income), net, are not allocated to segments.
For reconciliations of segment revenues and operating (loss) income to our consolidated results, see Note 15, Segment Information, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
57
Nuclear & Safety
| Unaudited | |||||||||||
| (In millions) | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||||
| Revenues | $ | 565.7 | $ | 419.7 | |||||||
| Income from operations | $ | 72.8 | $ | 62.0 | |||||||
| Income from operations as a % of revenues | 12.9 | % | 14.8 | % | |||||||
Nuclear & Safety segment revenues increased for the nine months ended September 30, 2026 compared with the nine months ended September 30, 2025 primarily due to $9.8 million of organic volume growth, with increases across all end markets with the exception of labs and research, positive foreign exchange fluctuations of $6.6 million, and $6.0 million of price increases. Additional drivers include $123.5 million of additional revenue from recent acquisitions.
Income from operations was $72.8 million and $62.0 million for the nine months ended September 30, 2026 and 2025, respectively. Income from operations increased $10.8 million period over period driven primarily by the increase in revenues described above and an improvement in gross margins from the prior period as a result of positive margin mix (primarily within our France and Europe locations). These changes were partially offset by a loss from operations associated with recent acquisitions (inclusive of purchase accounting intangibles amortization of $24.4 million).
Medical
| Unaudited | |||||||||||
| (In millions) | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||||
| Revenues | $ | 236.5 | $ | 228.3 | |||||||
| Income from operations | $ | 38.2 | $ | 28.3 | |||||||
| Income from operations as a % of revenues | 16.2 | % | 12.4 | % | |||||||
Medical segment revenues increased for the nine months ended September 30, 2026 compared with the nine months ended September 30, 2025 primarily due to $8.8 million of price increases, $8.6 million of organic volume growth within the cameras product line, and $0.8 million of positive foreign exchange fluctuations. These changes were partially offset by a decline in volume growth within other product lines of $10.0 million, specifically driven by a decline within Asia-Pacific countries due to the introduced tariff regime in prior years paired with a decline in dosimetry product sales.
Income from operations was $38.2 million and $28.3 million for the nine months ended September 30, 2026 and 2025, respectively, representing a $9.9 million increase in income from operations period over period. The increase in income from operations period over period was largely due to increased revenues as described above, a reduction in amortization expense of $1.9 million, and lower bad debt expense as compared with the prior year of $1.4 million. Partially offsetting the increase in income were increased employee compensation costs of $1.0 million.
Corporate and other
Corporate and other costs include costs associated with our corporate headquarters located in Georgia, as well as centralized global functions including Executive, Finance, Legal and Compliance, Human Resources, Technology, Strategy, and Marketing and other costs related to company-wide initiatives (e.g., Business Combination transaction expenses, merger and acquisition activities, restructuring and other initiatives).
Corporate and other costs were $72.2 million for the nine months ended September 30, 2026 and $64.3 million for the nine months ended September 30, 2025, which represents an increased loss of $7.9 million period over period. The increase versus the comparable period was predominantly driven by increased stock compensation costs of $5.7 million, including $3.8 million of additional expense related to PSOs granted during the current year, $3.8 million of costs associated with the establishment of a new artificial intelligence function, and $0.8 million of increased current period mergers and acquisition related expenses. These were partially offset by a $2.4 million decrease in research and development spend as employees were reassigned to research and development projects within the businesses.
58
For reconciliations of segment operating income and corporate and other costs to our consolidated results, see Note 15, Segment Information, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
Liquidity and Capital Resources
Overview of Liquidity
Our primary future cash needs relate to working capital, operating activities, capital spending, strategic investments, and debt service.
Mirion management believes that net cash provided by operating activities, augmented by long-term debt arrangements, will provide adequate liquidity for the next 12 months of independent operations, as well as the resources necessary to invest for growth in existing businesses and manage Mirion's capital structure on a short- and long-term basis. Access to capital and availability of financing on acceptable terms in the future will be affected by many factors, including our credit rating, economic conditions, and the overall liquidity of capital markets. There can be no assurance of continued access to financing from the capital markets on acceptable terms or at all.
At September 30, 2026 and December 31, 2025 we had $411.6 million and $415.2 million, respectively, in cash, cash equivalents, and restricted cash, which include amounts held by entities outside of the United States of approximately $225.6 million and $205.7 million, respectively, primarily in Europe and Canada. Non-U.S. cash is generally available for repatriation without legal restrictions, subject to certain taxes, mainly withholding taxes. We are asserting indefinite reinvestment of cash for certain non-U.S. subsidiaries. The Company has alternative repatriation options other than dividends should the need arise.
For more information on our lease commitments and other commitments and contingencies, see Note 10, Leased Assets, and Note 11, Commitments and Contingencies, respectively, of the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report Form 10-Q.
Debt Profile
2021 Credit Agreement
The Company maintains a credit agreement (the “2021 Credit Agreement”) among Mirion IntermediateCo Inc., a Delaware corporation, as Holdings, Mirion Technologies (US Holdings), Inc., as the Parent Borrower, Mirion Technologies (US), Inc., as the Subsidiary Borrower, the lending institutions party thereto, and Citibank, N.A., as the Administrative Agent and Collateral Agent.
The 2021 Credit Agreement, as amended, provides for an $830.0 million senior secured first lien term loan facility and a $175.0 million senior secured revolving facility (collectively, the “Credit Facilities”). The term loan facility is scheduled to mature on June 5, 2032, and the revolving facility is scheduled to expire and mature on March 21, 2030. The agreement requires the payment of a commitment fee of 0.50% per annum for unused revolving commitments, subject to stepdowns to 0.375% per annum and 0.25% per annum upon the achievement of specified leverage ratios. Any outstanding letters of credit issued under the 2021 Credit Agreement reduce the availability under the revolving line of credit.
The 2021 Credit Agreement is secured by a first priority lien on the equity interests of the Parent Borrower owned by Holdings and substantially all of the assets (subject to customary exceptions) of the borrowers and the other guarantors thereunder. Interest with respect to the facilities is based on, at the option of the borrowers, (i) a customary base rate formula for borrowings in U.S. dollars or (ii) a floating rate formula based on the Secured Overnight Financing Rate (“SOFR”) for borrowings in U.S. dollars, a floating rate formula based on Euro Interbank Offered Rate (“EURIBOR”) for borrowings in Euro or a floating rate formula based on the Sterling Overnight Index Average (“SONIA”) for borrowings in Pounds Sterling, each as described in the 2021 Credit Agreement with respect to the applicable type of borrowing.
The 2021 Credit Agreement contains customary representations and warranties as well as customary affirmative and negative covenants and events of default. The negative covenants include, among others and in each case subject to certain thresholds and exceptions, limitations on incurrence of liens, limitations on incurrence of indebtedness, limitations on making dividends and other distributions, limitations on engaging in asset sales, limitations on making investments, and a financial covenant that the “First Lien Net Leverage Ratio” (as defined in the 2021 Credit Agreement) as of the end of any fiscal quarter is not greater than 7.00 to 1.00 if on the last day of such fiscal quarter certain borrowings outstanding under the revolving credit facility exceed 40% of the total revolving credit commitments at such time. The covenants also contain limitations on the activities of Mirion IntermediateCo, Inc. as the “passive” holding company. If any of the events of default occur and are not cured or waived, any unpaid amounts under the 2021 Credit Agreement may be declared
59
immediately due and payable, the revolving credit commitments may be terminated and remedies against the collateral may be exercised. Mirion IntermediateCo, Inc. was in compliance with all debt covenants on September 30, 2026 and December 31, 2025.
Term Loan - The term loan had a remaining principal balance of $450.0 million as of September 30, 2026 and December 31, 2025. The term loan bore interest at the greater of SOFR or 0.50%, plus the applicable margin rate of 2.00%. The interest rate was 5.73% and 5.78% as of September 30, 2026 and December 31, 2025, respectively. The Company made no repayments during the nine months ended September 30, 2026 and repaid $244.6 million during the year ended December 31, 2025.
Revolving Line of Credit - There was no outstanding balance under the arrangement as of September 30, 2026 and December 31, 2025. Additionally, the Company has standby letters of credit issued under its 2021 Credit Agreement that reduce the availability under the revolver of $12.9 million and $15.7 million for the periods ended September 30, 2026 and December 31, 2025, respectively. The amount available on the revolver as of September 30, 2026 and December 31, 2025 was approximately $162.1 million and $159.3 million, respectively.
Convertible Senior Notes due 2030
On May 23, 2025, the Company completed a private offering of $400.0 million in aggregate principal amount of 0.25% Convertible Senior Notes due 2030, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2030 Notes”). The 2030 Notes were issued pursuant to an indenture, dated May 23, 2025 (the “Indenture”). The Indenture includes customary covenants and sets forth certain events of default after which the 2030 Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the outstanding principal and accrued interest of the 2030 Notes becomes automatically due and payable.
The 2030 Notes will mature on June 1, 2030, unless earlier converted, redeemed or repurchased. The 2030 Notes will bear interest from May 23, 2025 at a rate of 0.25% per year payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2025. The 2030 Notes will be convertible at the option of the holders in certain circumstances discussed below. The 2030 Notes will be convertible into cash, shares of Mirion’s Class A common stock or a combination of cash and shares of Mirion’s Class A common stock, at the Company’s election.
The initial conversion rate is 43.2751 shares of Mirion’s Class A common stock per $1,000 principal amount of 2030 Notes, which is equivalent to an initial conversion price of approximately $23.11 per share of Mirion's Class A common stock. The initial conversion price of the 2030 Notes represents a conversion premium of 32.5% to the last reported sale price of Mirion’s Class A common stock of $17.44 per share on May 20, 2025. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.
Convertible Senior Notes due 2031
On September 30, 2025, concurrently with an offering of Mirion's Class A common stock, the Company completed a private offering of $375.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2031, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2031 Notes”). The 2031 Notes were issued pursuant to an indenture, dated September 30, 2025 (the “September Indenture”). The September Indenture includes customary covenants and sets forth certain events of default after which the 2031 Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the outstanding principal and any unpaid special interest of the 2031 Notes becomes automatically due and payable.
The 2031 Notes will mature on October 1, 2031, unless earlier converted, redeemed or repurchased. The 2031 Notes will not bear regular interest, and the principal amount of the 2031 Notes will not accrete. Special interest will accrue on the 2031 Notes in the circumstances at the rates set forth within the September Indenture. The 2031 Notes will be convertible at the option of the holders in certain circumstances discussed below. The 2031 Notes will be convertible into cash, shares of Mirion’s Class A common stock or a combination of cash and shares of Mirion’s Class A common stock, at the Company’s election.
The initial conversion rate is 34.6951 shares of Mirion’s Class A common stock per $1,000 principal amount of 2031 Notes, which is equivalent to an initial conversion price of approximately $28.82 per share of Mirion's Class A common stock. The initial conversion price of the 2031 Notes represents a conversion premium of 35.0% to the related public offering price per share of Mirion Class A common stock of $21.35 per share. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the September Indenture.
60
Convertible Senior Notes - Redemption
The Company may not redeem the 2030 Notes prior to June 6, 2028 and the 2031 Notes prior to October 5, 2028. The Company may redeem for cash 100% of the principal amounts of the 2030 Notes and 2031 Notes being redeemed plus any unpaid special interest or any portion of the principal at its option, on or after the applicable redemption date, but only if a certain liquidity condition has been satisfied and the last reported sale price of Mirion's Class A common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period. If the Company redeems less than all of the outstanding notes, at least $100.0 million aggregate principal amount of the respective notes must be outstanding and not subject to redemption as of, and after giving effect to, delivery of the relevant redemption notice.
If the Company undergoes a fundamental change, as defined in the May and September Indentures, then subject to certain conditions and limited exceptions, holders may require the Company to repurchase for cash all or any portion of their notes in principal amounts of $1,000 or an integral multiple thereof at a repurchase price equal to 100% of the principal amount of the notes to be repurchased plus any accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity dates or if the Company issues a notice a redemption, the Company will increase the conversion rate for holders who elect to convert their notes in connection with such a corporate event. The conditions allowing holders of the 2030 Notes and 2031 Notes to convert were not met during the three and nine months ended September 30, 2026.
Convertible Senior Notes - Interest and Maturity
The 2030 Notes and 2031 Notes are classified as long-term liabilities, net of issuance costs of $9.1 million and $8.3 million, respectively, as of September 30, 2026, and $12.4 million and $9.9 million, respectively, as of December 31, 2025, on the unaudited Condensed Consolidated Balance Sheets. As of September 30, 2026 and December 31, 2025, the net carrying amount of the 2030 Notes and 2031 Notes approximates fair value. As the 2030 Notes and 2031 Notes were not issued at a premium, no portion of the proceeds from the issuance of the 2030 Notes and 2031 Notes met the requirements to be accounted for separately as a component of stockholders’ equity. The 2030 Notes and 2031 Notes were issued at par, and costs associated with the issuance of the 2030 Notes and 2031 Notes are amortized to interest expense over the contractual term of the respective Notes. Interest expense (including amortization of deferred issuance costs) recognized related to the 2030 Notes for the three and nine months ended September 30, 2026 was $0.9 million and $2.6 million, respectively and $0.9 million and $1.3 million for the three and nine months ended September 30, 2025, respectively. No special interest was recorded for the 2031 Notes and amortization of deferred financing costs of $0.4 million and $1.2 million was recorded for the 2031 Notes during the three and nine months ended September 30, 2026. As of September 30, 2026, the effective interest rate of the 2030 Notes is 0.88%.
For more discussion on the Company's debt profile, see Note 8, Borrowings, and Note 9, Convertible Debt, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
Share Repurchase Programs
In December 2024, we instituted a share repurchase program for up to $100 million of the currently outstanding shares of our Class A common stock, as approved by our Board of Directors and authorized until November 14, 2029 (the “2024 Repurchase Program”). Repurchases under the 2024 Repurchase program commenced in February 2025 and were completed during the three months ended September 30, 2026, with 5,937,716 shares of our Class A common stock repurchased cumulatively for $100.0 million.
On August 31, 2026, we announced the approval of a new share repurchase program of up to an additional $250 million of the currently outstanding shares of our Class A common stock, as approved by our Board of Directors and authorized until August 31, 2031 (the “2026 Repurchase Program”). We have repurchased 963,371 of our Class A common stock under the 2026 Repurchase Program as of September 30, 2026 for $15.4 million.
61
Hedges
The Company’s policy requires derivatives to be used solely for managing risks and not for speculative purposes. As a result of the Company’s European operations, the Company is exposed to fluctuations in exchange rates between EUR and USD. As such, the Company entered into two cross-currency rate swaps during the year ended December 31, 2022, to manage currency risks related to our investments in foreign operations. During the year ended December 31, 2025, the Company extended one cross-currency rate swap derivative by 2 years. During the nine months ended September 30, 2026, the Company extended the other cross-currency rate swap derivative by thirty-three months. The Company is also subject to interest rate risk related to the Credit Facilities. The Company manages its risk to interest rate fluctuations through the use of derivative financial instruments. As such, the Company entered into an interest rate swap (notional amount of $75.0 million) during the year ended December 31, 2023 (settled during the three months ended June 30, 2026), as well as an additional interest rate swap (notional amount of $100.0 million) during the year ended December 31, 2025 (scheduled to settle during the fourth quarter of 2026), to mitigate the risk of adverse changes in benchmark interest rates on the Company’s future interest payments (collectively, the “interest rate swaps”).
The cross-currency rate swaps are derivative financial instruments that have been designated and qualify as hedges of net investments in our foreign operations. Accordingly, the changes in the fair values of the swaps are recognized in net investment hedges adjustments, a component of accumulated other comprehensive loss (“AOCL”), to offset the changes in the values of the net investments being hedged. Any ineffective portions of net investment hedges are reclassified from AOCL into earnings during the period of change. The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges (in millions):
| Notional Amount | Gain (Loss) Recognized in AOCL | ||||||||||||||||||||||||||||||||||
| As of | Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||||||||||||||||||||||||||
| September 30, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||||||||
| Cross-currency rate swaps | € | 238.8 | € | 238.8 | $ | 2.8 | $ | 0.5 | $ | 10.3 | $ | (31.1) | |||||||||||||||||||||||
| Total | € | 238.8 | € | 238.8 | $ | 2.8 | $ | 0.5 | $ | 10.3 | $ | (31.1) | |||||||||||||||||||||||
The interest rate swaps are derivative financial instruments that have been designated and qualify as cash flow hedges. The changes in the fair values of the cash flow hedges are recorded in accumulated other comprehensive loss (“AOCL”) and are reclassified into the line item in our unaudited Consolidated Statements of Operations in which the hedged items are recorded in the same period the hedged items affect earnings. The changes in the fair values of hedges that are determined to be ineffective are immediately reclassified from AOCL into earnings.
No gains or losses were recognized in other comprehensive income ("OCI") during the three months ended September 30, 2026, and gains of $0.3 million were recognized for the nine months ended September 30, 2026 as a result of the interest rate swaps. No gains or losses were recognized in income during the three months ended September 30, 2026 and gains of $0.2 million were recognized in income through interest expense and reclassified from OCI during the nine months ended September 30, 2026.
For more discussion of the hedges of net investments, see Note 16, Fair Value Measurement, and Note 17, Derivatives and Hedging, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.
Cash Flows
For the Nine Months Ended September 30, 2026 and for the Nine Months Ended September 30, 2025
| Unaudited | |||||||||||
| (In millions) | Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||||
| Net cash provided by operating activities | $ | 136.6 | $ | 70.3 | |||||||
| Net cash used in investing activities | $ | (31.7) | $ | (103.8) | |||||||
| Net cash (used in) provided by financing activities | $ | (102.3) | $ | 778.7 | |||||||
62
Net Cash Provided by Operating Activities
Net cash provided by operating activities was $136.6 million for the nine months ended September 30, 2026 as compared to net cash provided by operating activities of $70.3 million for the nine months ended September 30, 2025, representing an increase of $66.3 million. The change is primarily due to the cash impact from net income, adjusted for non-cash items, increasing by $43.0 million and $23.3 million in additional cash inflow from changes in various items in net working capital.
Net Cash Used in Investing Activities
Net cash used in investing activities was $31.7 million for the nine months ended September 30, 2026 versus $103.8 million for the nine months ended September 30, 2025 representing a decrease of $72.1 million. The decrease in net cash used was driven primarily by $79.7 million in additional outflow for the acquisition of the Certrec business in the prior year partially offset by a $5.2 million in additional capital expenditures.
Net Cash (Used in) Provided by Financing Activities
Net cash used in financing activities was $102.3 million during the nine months ended September 30, 2026 versus net cash provided by financing activities of $778.7 million during the nine months ended September 30, 2025. The change of $881.0 million period over period primarily relates to the net cash inflows in the prior year debt transactions described above in the Liquidity and Capital Resources section ($754.1 million from the issuance of convertible senior notes net of issuance costs and $410.1 million from the issuance of common stock net of issuance costs, offset by term loan principal repayments of $244.6 million, and $82.6 million of purchases of capped calls related to convertible senior notes). Additionally, there was $47.2 million more in cash outflows from repurchases of Company stock compared to the prior year.
Critical Accounting Policies and Estimates
Our consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. Such estimates are based on historical experience and on various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these judgments and estimates under different assumptions or conditions and any such differences may be material.
During the nine months ended September 30, 2026, there were no material changes to our critical accounting policies and estimates from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K.
Recent Accounting Pronouncements
See Note 1, Nature of Business and Summary of Significant Accounting Policies, to our unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q for more information.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Quantitative and Qualitative Disclosures about Market Risk
We have no material changes to the disclosures on this matter for the three months ended September 30, 2026, than from the disclosures made in our Annual Report on Form 10-K for the year ended December 31, 2025.
63
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that material information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
As required by Rules 13a-15(b) and 15d-15(b) under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2026, our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Control Over Financial Reporting
There were no changes to our internal control over financial reporting (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
64
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Due to the nature of our activities, we are at times subject to pending and threatened legal actions that arise out of the ordinary course of business. For information regarding legal proceedings and other claims in which we are involved, see Note 11, Commitments and Contingencies, to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q. The disposition of any such currently pending or threatened matters is not expected to have a material effect on our business, results of operations or financial condition. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that our business, results of operations and financial condition could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions. Regardless of the outcome, litigation can have an adverse impact on our business because of defense and settlement costs, diversion of management resources and other factors. In addition, the expense of litigation and the timing of this expense from period to period are difficult to estimate, subject to change and could adversely affect our consolidated financial statements.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors”, in our Annual Report on Form 10-K for the year ended December 31, 2025, as further updated and supplemented below, which could materially affect our business, results of operations, and financial condition. These risks are not the only risks facing our Company. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, could also materially adversely affect our business, financial condition or future results.
Our operating results may be impacted by the effects of, and changes in, worldwide economic conditions, geopolitical tensions, international trade, tariffs and retaliatory countermeasures, export controls, foreign localization requirements and other trade barriers, global trade wars or domestic preferences, any of which could increase our costs and materially and adversely affect our business, results of operations and financial condition. Our global business, operations, and the execution of our business strategies and plans are subject to global competition and economic and geopolitical risks that are beyond our control, such as, among other things, tariffs and retaliatory countermeasures, trade barriers and other governmental protectionist measures impacting international trade agreements or imposing trade restrictions, including requirements that our equipment be localized or sourced in-country for public tenders opportunities, any of which can negatively affect us. Geopolitical tensions, including the ongoing conflict involving Iran, have contributed to uncertainty in the broader macroeconomic environment, including volatility in energy markets and continued concerns regarding inflation and interest rates. Additionally, heightened geopolitical tensions and uncertainties related to trade wars have caused economic disruption and uncertainty, which may impact customer spending, project timing, and overall demand for the Company's products. These factors may continue to negatively affect our financial results and operating cash flows. We are unable to predict the extent or duration of these impacts, including the effect of any further escalation or related governmental or market responses, on our business, financial condition and results of operations.
There is currently significant uncertainty about future trade relationships between the United States and various other countries, most significantly Russia, Canada, Mexico, and China. Further escalation of specific trade tensions, including those between the U.S. and China, or more broadly in global trade conflicts, could materially and adversely affect the Company’s business and operations. The U.S. government and other governments have imposed export controls and tariffs on certain products and certain components that we import into, and export out of, the United States, and we, our customers, suppliers, and partners may become subject to additional tariffs and export controls and our products and services may be subject to increased competition outside of the United States. China continues to expand localization requirements that could require us to localize manufacturing or source local components, or to otherwise modify our business operations. Compliance with those requirements could increase our costs or delay or prevent sales and reduce demand for our equipment. In addition, geopolitical tensions could result in, among other things, cyberattacks, supply chain disruptions, higher energy and other commodity costs, lower demand, changes to foreign exchange rates and financial markets. Additional tariffs and trade restrictions may result in increased manufacturing costs and product pricing, further supply chain disruptions, limit access to end markets and lower profitability. We also generate a significant amount of our revenue outside of the United States which may be adversely affected by tariffs and trade controls imposed by other countries. Revenue generated from outside of North America accounted for approximately 28.4% of our net sales for the quarter ended September 30, 2026 and approximately 37% of our net sales for the year ended December 31, 2025, and international sales are expected to remain a material percentage of our total revenue in future periods. If we are not successful in offsetting the impact of tariffs, export controls, trade barriers, localization requirements and other geopolitical disruptions, our business, results of operations and financial condition may be adversely affected.
65
The use of Artificial Intelligence (AI) and machine learning technologies in our business and operations may result in legal liability, regulatory action, increased compliance obligations, competitive or reputational harm, ethical or other concerns and adversely affect our business, financial condition and results of operations. We use artificial intelligence, including generative artificial intelligence and machine learning technologies, such as deep learning, in certain business operations and rely on third-party products and services that incorporate artificial intelligence technologies. Artificial intelligence systems, particularly generative artificial intelligence and artificial intelligence tools used in software development, may produce inaccurate, biased, misleading, incomplete, or defective outputs, including code errors, security vulnerabilities or intellectual property issues, and reliance on such outputs or on artificial intelligence systems designed, trained, operated or used by vendors or other third parties could expose us to liability, regulatory scrutiny or reputational harm. In particular, security vulnerabilities in our, or vendor generative AI tools, may create attack vectors exposing our data and/or systems. Artificial intelligence tools may also mishandle sensitive information in ways which could have an adverse effect on our business, results of operations and financial condition.
If competitors or other third parties adopt artificial intelligence more quickly or effectively than us, our competitive position, reputation and operations could be adversely affected. Further, there can be no assurance that our use of artificial intelligence will increase our efficiency or profitability as its cost increases, or be beneficial to our business.
Laws and regulations governing artificial intelligence technologies are rapidly evolving and complex, including in the areas of intellectual property, cybersecurity, privacy and data protection, employment, consumer protection, product liability, securities, defamation and other areas. Existing and proposed laws and regulations in the United States and the European Union, including the European Union’s Artificial Intelligence Act and a growing number of U.S. state artificial intelligence laws, may impose additional governance, transparency, assessment, monitoring, reporting and other compliance obligations on companies that develop, deploy or use artificial intelligence tools, including third-party artificial intelligence tools.
Although we have implemented and continue to enhance policies, procedures and governance controls intended to help address certain risks presented by these technologies, our employees may not fully abide by those controls and these measures may not fully address or prevent legal, regulatory, operational, reputational, ethical or other risks. Compliance with evolving artificial intelligence laws, regulations and industry standards relating to artificial intelligence may impose significant costs, require changes to our governance processes or business practices, limit our ability to develop, deploy or use artificial intelligence technologies in our business, or expose us to regulatory inquiries, investigations, enforcement actions, litigation or other claims. There has been an increase in artificial intelligence-related litigation and government regulatory actions targeting the design, deployment and other uses of artificial intelligence and claiming liability under numerous areas of law, such as consumer protection, product liability, privacy, intellectual property, employment, securities, and defamation. Any of these risks could have an adverse effect on our business, results of operations and financial condition.
Our growth strategy depends in part on plans to supply our products and services to small modular reactors ("SMRs") and other advanced reactors in the United States, an emerging market that may grow more slowly than we expect. Sales to SMRs and advanced reactor developers are currently a small but growing part of our business and our strategy assumes this share will increase over time. We have pursued agreements with a number of companies building SMRs, but they face commercialization obstacles, including reactor design, regulatory licensing, and securing customers willing and able to make large investments in emerging nuclear technologies. Many rely significantly on government support for licensing, fuel production, and first-of-a-kind construction. If political support for nuclear energy declines or funding or tax incentives change, our SMR and advanced reactor partners may be unable to obtain the financing they require, which could cause them to delay, scale back, or cancel projects and reduce demand for our products and services. Many of these companies are also publicly traded with volatile stock prices, and a sustained decline could impair their ability to raise the capital needed to carry out their plans, and some are also new entrants that may fail operationally even if they develop a successful reactor, which could harm the broader market. If these risks materialize, demand for our products and services in this market may develop more slowly than we expect, or not at all. Any of the foregoing could have an adverse effect on our business, results of operations, and financial condition.
Supply chain issues, including electronic component shortages driven by artificial intelligence and data center demand, could disrupt production, cause delays and increase costs for the commodities or components that we use in our operations which may materially and adversely impact our business, results of operations and financial condition. We rely on third-party suppliers for our manufacturing operations including from sole or limited source suppliers due to quality assurance, cost effectiveness, availability, contractual obligations or unique design or technology. Suppliers’ capacity constraints and decreased availability of key materials could cause increased expenses, production interruptions, delays, extended lead times, and inefficiencies, and adversely impact our business, results of operations and financial condition. In particular, our products incorporate electronic components, for which demand has increased significantly due to global investment in artificial intelligence and the rapid expansion of hyperscale data center infrastructure. As suppliers prioritize capacity for these allocations, we have experienced, and may continue to experience, reduced availability, longer and less
66
predictable lead times, accelerated obsolescence and higher costs for certain components. These constraints could delay our production and deliveries, impair our ability to meet customer demand and contractual commitments, delay revenue recognition, compress margins on our fixed-price and limited price-escalation contracts, and cause our results of operations to fluctuate. Although we seek to mitigate these risks through supplier relationships, dual-sourcing, strategic inventory purchases, and pricing actions, these measures may be insufficient.
We derive a significant portion of our revenue from international sales and our operations in non-U.S. countries are subject to political, economic, legal, currency and other risks, which could materially and adversely affect us. Revenue generated from outside of North America accounted for approximately 37%, 37%, and 36% of our net sales for the years ended December 31, 2025, December 31, 2024, and December 31, 2023, respectively. International sales are expected to remain a material percentage of our total net sales in future periods. Regional political and economic instability can impact these operations. In particular, we have significant revenue and operations in Europe, including France, where we are exposed to economic weakness in the Eurozone, political and fiscal uncertainty (including government budget and sovereign credit pressures), and social unrest, strikes and other labor actions. These factors could disrupt our operations, increase our costs, limit the financing our customers depend on and reduce demand for our products or compress our margins, and adversely affect our business, results of operations and financial condition.
67
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
(a) Not applicable.
(b) Not applicable.
(c) Under share repurchase programs, the Company intends to repurchase shares from time to time through open market purchases, privately negotiated transactions, block purchases and otherwise in accordance with applicable federal securities laws, including Rules 10b5-1 and 10b-18 of the Exchange Act. During the three months ended September 30, 2026, Mirion repurchased 3,597,964 shares of its Class A common stock, par value $0.0001 per share, under publicly announced programs. See Liquidity and Capital Resources for further information on our publicly announced share repurchase programs. The following table summarizes the repurchases of the Company's Class A common stock during the three months ended September 30, 2026:
Issuer Purchases of Equity Securities
| Period | (a) Total number of shares purchased | (b) Average price paid per share | (c) Total number of shares purchased as part of publicly announced plans or programs | (d) Approximate dollar value of shares that may yet be purchased under plans or programs (in millions) | ||||||||||||||||||||||
| July 1 - 31, 2026 | — | $ | — | — | $ | 40.4 | ||||||||||||||||||||
| August 1 - 31, 2026 | 2,597,929 | $ | 15.33 | 2,597,929 | $ | 250.6 | ||||||||||||||||||||
| September 1 - 30, 2026 | 1,000,035 | $ | 15.99 | 1,000,035 | $ | 234.6 | ||||||||||||||||||||
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
(a) None.
(b) None.
(c) During the three months ended September 30, 2026, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted or terminated
| Name and Title | Action | Applicable | Duration of Trading Arrangement | Rule 10b5-1 Trading Arrangement? (Y/N)(1) | Aggregate Number of Securities Subject to Trading Arrangement | ||||||||||||
| December 9, 2026 - March 30, 2028 | Y | up to | |||||||||||||||
(1) Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).
(2) Reflects the maximum aggregate number of gross shares underlying restricted stock unit and performance stock unit awards (performance stock units shown at target) that vest in 2027 and 2028 and are subject to the trading arrangement. Upon vesting, the Company will withhold shares to satisfy tax withholding obligations and only the net remaining shares will be sold; the number of shares actually sold will be less than the number shown and cannot be determined until the vesting events occur.
68
ITEM 6. EXHIBITS
The exhibits listed on the accompanying Exhibit Index are filed or incorporated by reference as part of this Quarterly Report.
69
EXHIBIT INDEX
Exhibit Number | Exhibit Title | ||||
| 101.INS* | XBRL Instance Document. | ||||
| 101.SCH* | XBRL Taxonomy Extension Schema Document. | ||||
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document. | ||||
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Document. | ||||
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase Document. | ||||
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document. | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | ||||
| * | Filed herewith. | ||||
| + | Indicates a management contract or compensatory plan | ||||
| ** | The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, irrespective of any general incorporation language contained in such filing. | ||||
70
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Mirion Technologies, Inc.
| Name | Title | Date | ||||||
/s/ Thomas D. Logan Thomas D. Logan | Chief Executive Officer and Director (principal executive officer) | October 28, 2026 | ||||||
/s/ Brian Schopfer Brian Schopfer | Chief Financial Officer (principal financial officer) | October 28, 2026 | ||||||
/s/ Christopher Moore Christopher Moore | Chief Accounting Officer (principal accounting officer) | October 28, 2026 | ||||||
71
Exhibit 10.1
MIRION TECHNOLOGIES, INC.
Fourth Amended and Restated Non-Employee Director Compensation Program
August 5, 2026
The Compensation Committee of the Board of Directors (the “Board”) of Mirion Technologies, Inc. (the “Company”), recommended that the Board approve the following amended and restated director compensation program (this “Program”) for Non-Employee Directors of the Company, and the Board approved this Program effective August XX, 2026. For purposes of this Program, a “Non-Employee Director” is a director who has not served as an employee or executive officer of the Company or its affiliates or otherwise provided services to the Company or its affiliates in a capacity other than as a director at any time during the preceding year. This Program supersedes and replaces all prior non-employee director compensation programs of the Company.
1.Purpose. This Program is designed to attract and retain experienced, talented individuals to serve on the Board. The Compensation Committee will generally review director compensation on an annual basis, and consistent with its charter, develop and recommend to the Board for approval the compensation of the Company’s directors. This Program, as it may be amended from time to time, may take into account the time commitment expected of Non-Employee Directors, best practices in board member compensation, the economic position of the Company, broader economic conditions, market rates of board member compensation, historical compensation structure, the advice of the compensation consultant that the Compensation Committee or the Board may retain from time to time, and the potential dilutive effect of equity awards on our stockholders. Under this Program, Non-Employee Directors receive cash and equity compensation to recognize their day to day contributions, recognizing the level of responsibility as well as the necessary time commitment involved in serving in a leadership role and/or on committees. Consistent with our philosophy on executive compensation, we believe that stock ownership by Non-Employee Directors provides an incentive to act to maximize long-term stockholder value instead of short-term gain. Further, we believe that stock-based awards are essential to attracting and retaining talented Board members.
2.Cash Compensation. Each Non-Employee Director will be entitled to receive the following cash compensation (collectively, each Non-Employee Director’s “Cash Fee”):
a.All Non-Employee Directors. Each Non-Employee Director will be entitled to receive annual cash compensation in an amount equal to $ 76,500, accruing and payable on a quarterly basis at the end of each calendar quarter of service, as an annual retainer for his or her Board service.
b.Audit Committee Chair. In addition to the compensation provided under any other provision of this Program, the chairperson of the Audit Committee will be entitled to receive annual cash compensation in an amount equal to $22,500 accruing and payable on a quarterly basis at the end of each calendar quarter of service, as an annual retainer for his or her service as chairperson of the Audit Committee.
c.Compensation Committee Chair. In addition to the compensation provided under any other provision of this Program, the chairperson of the Compensation Committee will be entitled to receive annual cash compensation in an amount equal to $15,000 accruing and payable on a quarterly basis at the end of each calendar quarter of service, as an annual retainer for his or her service as chairperson of the Compensation Committee.
d.Nominating and Corporate Governance Committee Chair. In addition to the compensation provided under any other provision of this Program, the chairperson of the Nominating and Corporate Governance Committee will be entitled to receive annual cash compensation in an amount equal to $12,500 accruing and payable on a quarterly basis at the end of each calendar quarter of service, as an annual retainer for his or her service as chairperson of the Nominating and Corporate Governance Committee.
e.Lead Independent Director. In addition to the compensation provided under any other provision of this Program, the Lead Independent Director will be entitled to receive annual cash
1
Exhibit 10.1
compensation in an amount equal to $36,500 accruing and payable on a quarterly basis at the end of each calendar quarter of service, as an annual retainer for his or her service as Lead Independent Director.
In the event a Non-Employee Director does not serve as a Non-Employee Director, or in any of the applicable positions described above, for an entire calendar quarter, the Cash Fee paid to such Non-Employee Director shall be pro-rated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such other position, as applicable.
3.Equity Compensation. Each Non-Employee Director will receive the following equity awards under the Company Omnibus Incentive Plan (the “Plan”) as consideration for service on the Board. Each equity award granted under this Program (an “Award Agreement”) will be made in accordance with the Plan and will individually be approved by the Board or the Compensation Committee. Vesting of all equity awards granted under this Program will be as specified in the Award Agreement and will be subject to the Company’s standard form of Award Agreement, as most recently adopted by the Board or Compensation Committee for use under this Program.
a.Annual Equity Awards. Each year, the Board or Compensation Committee will grant each continuing Non-Employee Director Restricted Stock Units (“RSUs”) with a grant date fair market value of $180,000 which will vest annually, subject to the Non-Employee Director’s continued service through the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the annual stockholder meeting following the grant date. Such annual equity awards will ordinarily be approved in conjunction with the annual stockholder meeting.
b.Initial Equity Award. If a new Non-Employee Director is elected or appointed to the Board at a time other than at the annual stockholder meeting, then the Board or Compensation Committee will grant the new Non-Employee Director an award of RSUs equal to the product of $180,000 and a fraction with (i) a numerator equal to the number of days between the date of the Director’s initial election or appointment to the Board and the date which is the first anniversary of the date of the most recent annual stockholder meeting occurring before the new Non-Employee Director is elected or appointed to the Board, and (ii) a denominator equal to 365.
4.Equity Compensation in Lieu of Cash Fee. Each Non-Employee Director may elect to receive all of his or her Cash Fee in the form of shares of the Company’s Class A common stock (“Shares”) granted under the Plan. The receipt of Shares in lieu of cash is subject to the Company’s receipt of the applicable Non-Employee Director’s prior written election pursuant to an election form, as follows:
a.If a Cash Fee is elected to be payable in Shares (the “Stock Fee”), the applicable Non-Employee Director will receive his or her Stock Fee (each installment, a “Quarterly Stock Fee”), on the last day of each of the four calendar quarters immediately following the date of the most recent annual meeting of the Company’s stockholders for the period in respect of which the Cash Fee would otherwise be payable (or for a Non-Employee Director who commences service with the Company at any time after the most recent annual meeting of the Company’s shareholders, on the last day of each partial and full calendar quarter since such service with the Company commenced and in respect of which the Cash Fee would be payable) (each such date, a “Stock Fee Grant Date”).
b.The number of Shares subject to a Quarterly Stock Fee shall be calculated by dividing (A) the amount of the applicable Cash Fee that would otherwise have been paid in respect of the applicable calendar quarter by (B) the closing price of a Share on the last trading day immediately prior to the Stock Fee Grant Date, rounding down to the nearest whole Share. In the event that a Non-Employee Director does not serve as a Non-Employee Director, or in any of the applicable positions described above, for an entire calendar quarter, the number of Shares subject to the Quarterly Stock Fee to be awarded to such Non-Employee Director in respect of such calendar quarter shall be pro-rated for the portion of such calendar quarter actually served as a Non-Employee Director in the same manner as the applicable Cash Fee would be pro-rated for such period.
2
Exhibit 10.1
c.All elections by Non-Employee Directors between receiving a Cash Fee and Shares may only be made at a time (i) that is within any period commencing on the second business day following the publication of an earnings release from the Company with respect to the preceding fiscal period and ending on the 14th calendar day of the last month of the then current fiscal quarter and (ii) that the Non-Employee Directors are not otherwise restricted from trading by the Company’s insider trading policy. In addition, elections must be made by no later than the date of the next scheduled annual meeting of the Company’s stockholders; except that an initial election may be made within thirty (30) days of the date on which an individual becomes initially eligible to participate in this program. In the absence of a timely election to receive his or her Cash Fee in the form of Shares, the Board member will receive applicable fees in cash in accordance with Section 2 above.
d.Elections shall be irrevocable after the applicable deadline, and any election to receive the Cash Fee in the form of Shares must be as to the entire amount of the Cash Fee, with no partial elections between the two forms of payment.
e.Elections shall be effective solely as to Cash Fees payable during the period commencing immediately following the next annual meeting of the Company’s stockholders and ending on the date of the subsequent annual meeting of the Company’s stockholders.
Expenses. The Company will reimburse Directors for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board meetings, in accordance with the Company’s applicable expense reimbursement policies and procedures as in effect from time to time.
3
Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Thomas D. Logan, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Mirion Technologies, Inc.
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;
4.The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: October 28, 2026
| By: | /s/ Thomas D. Logan | ||||
| Name: | Thomas D. Logan | ||||
| Title: | Chief Executive Officer | ||||
| (Principal Executive Officer) | |||||
Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Brian Schopfer, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Mirion Technologies, Inc.
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;
4.The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: October 28, 2026
| By: | /s/ Brian Schopfer | ||||
| Name: | Brian Schopfer | ||||
| Title: | Chief Financial Officer | ||||
| (Principal Financial Officer) | |||||
Exhibit 32.1
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
In connection with the Quarterly Report on Form 10-Q of Mirion Technologies, Inc. (the “Company”), for the period ended September 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Thomas D. Logan, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: October 28, 2026
| By: | /s/ Thomas D. Logan | ||||
| Name: | Thomas D. Logan | ||||
| Title: | Chief Executive Officer | ||||
| (Principal Executive Officer) | |||||
Exhibit 32.2
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
In connection with the Quarterly Report on Form 10-Q of Mirion Technologies, Inc. (the “Company”), for the period ended September 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Brian Schopfer, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: October 28, 2026
| By: | /s/ Brian Schopfer | ||||
| Name: | Brian Schopfer | ||||
| Title: | Chief Financial Officer | ||||
| (Principal Financial Officer) | |||||